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Session A1: Changing Pathology of Ageing Society
Invited lecture
A1-I
Evolving Needs in Pathology 
Education
Ambrogio Fassina
Dpt of Medicine, Section of Pathology, University of Padova, Italy
History of medicine is evidently and strongly con-
nected with the history of human thinking, connec-
tion and collaboration with other sciences such phys-
ics and chemistry. Pathology as well was and is depen-
dent and involved in technology evolution from its 
very beginning (Table 1).
Table 1
1591 compound microscope
1673 Anton van Leeuwenhoek simple microscopes  
with single lenses
1848 first microtome (for animal tissues)
1885 Cambridge Rocker microtome
1886 minot microtome
1910 sledge microtomes
mid1800s paraffin wax for infiltration and support clocks
1893 first use of formalin
staining hematoxilin and eosin
silver impregnation
Last century approach is basically still in use for 
nowadays routine diagnostic, with significant changes 
in time and quality, but slide preparation for surgical 
pathology is still artisanal and human dependent. In 
the sixties of last century, biology introduced the pro-
tein purification and the development of antibodies 
against antigens of cell component, and immunohisto-
chemistry changed the diagnostic perspective, bring-
ing pathology in the real circuit of medical decision 
about prognosis and therapy. More recently, biology, 
physics, statistics and chemistry introduced new tools 
in the approach to human tissues that again obliged to 
move to different requests from clinicians and a differ-
ent expertise of pathologists.
In the meanwhile, the pathology laboratories grew 
in terms of manpower number and expertise of the 
technical personnel and in terms of machinery, both 
for sample handling and preparation and for preana-
lytical, analytical control and finally for Informatics 
for communication to colleagues and patients.
Medical Education is a national prerogative, but the 
need for harmonization in Training Programs is an 
obligation in order to more satisfactorily fulfill the Bo-
logna Declaration about the free movements of Doc-
tors in all EU countries.
Union Européenne des Medecins Specialists (UEMS) 
produced European Training Requirements (ETR) 
for each Medical Specialty, and last year the Patholo- 
gy ETRs were approved during the UEMS General 
 Assembly in London. (https://www.eums.eu/_data/ 
assests/pdf_file/0006111795/UEMS-2019.44-Europe-
an-TRaining-Requirements-on-Pathology.pdf), where 
three areas were identified, namely the Residency pro-
gram and achievements, the trainers and the training 
center qualifications and facilities. In these ETRs, we 
stressed that pathology is a specialty in which time, 
pre-analytical and technical procedures are critical, 
in the everyday routine practice and when during 
open surgery the modality choice and the rapid on-site 
evaluation of a frozen section require skills and high-
est scientific preparation of the dedicated specialist.
Pathology encompasses knowledge and skills of sur-
gical pathology, autopsy pathology and cytopathology 
and additional competences in areas of special interest 
such as dermatopathology, forensic pathology, neu-
ropathology, paediatric pathology, cardiovascular pa-
thology and paleopathology.
Finally, patient education and public health aspects 
must be also be considered.
Nowadays, is clear how pathology plays a funda-
mental role in modern healthcare systems, addressing 
the comprehensive diagnostic needs of all patients, 
 coordinating and directing the therapy choices. The pa-
thologist must possess not only the essential scientific 
knowledge and skills necessary for complete and cor-
rect diagnosis, but also the organizational insights and 
capabilities needed to work efficiently in the pathology 
laboratory/department, cytopathology office, the 
autoptic and forensic department, additionally joined 
with molecular biology facility and other modern tech-
nologies (eg. bioinformatics, biobanking).
Obvious knowledge and data from Hospitals all 
around the world were confirmed by a rapid survey of 
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the activity of the Department of Medicine, Section of 
Pathology and Cytopathology of Padova University 
clearly demonstrating the evident increase of disease 
in advancing age.
The problem of aging is common for the entire 
world. The problem of rapid population aging is espe-
cially pressing in China, as its population aging rate 
and aging dependency growth are among the fastest in 
the world, with the absolute number of the elderly 
being the largest in the world (about 167 million or 
12% of the country population over 65 in 2019, which 
will grow to as much as 330 million or about 26% by 
2050). As the aging health problems increase, so do in-
However, this evidence appears to be sort of neglect-
ed in the EU education system, at the contrary for in-
stance to the attention given to the medicine of gender, 
and, at least in Italy, the few gerontology departments 
have been closed and patients transferred to general 
internal medicine wards. Advanced age is not a dis-
ease, instead should be regarded as a resource, but if 
“advanced aged” subjects become patients, their dis-
eases should be reconsidered with the psychological 
attitudes, social and familiar situation, mental and 
physical performance status, along with the character-
istics of the disease.
R e f e R e n c e s
1. Engels M, Michael C, Dobra K, et al. Management of cytologi-
cal material, pre-analytical procedures and bio-banking in ef-
fusion cytopathology. Cytopathology. 2019 Jan;30(1):31–38.
2. Fassina A, Cappellesso R, Tötsch M, et al. Next-generation 
learning and training: The Cy-TEST experience. Cancer Cyto-
pathol. 2017 Sep;125(9):669–67.
3. Salto-Tellez M, Cree IA. Cancer taxonomy: pathology beyond 
pathology. Eur J Cancer. 2019;115:57–60.
A1-II
Changing Pathology of Ageing 
Society
Claude Cuvelier
Pathology Department, Ghent University, Belgium
The world is facing an unprecedented situation! 
There are more older people than children and more 
people at extreme old age than ever before. As the pro-
portion of older people and the length of life increase 
throughout the world, key questions arise. Will popu-
lation ageing be accompanied by a longer period of 
good health, a sustained sense of well-being, extended 
periods of social engagement and productivity, or will 
World Population Prospects 2019:
•  Confirms that the world’s population continues to grow, albeit  
at a slowing rate;
•  Points to the challenges facing some countries and regions 
related to rapid population growth driven by high fertility;
•  Notes that population size is decreasing in some countries  
due to sustained low fertility or emigration;
•  Underscores the opportunities available to countries where  
a recent decline in fertility is creating demographic conditions 
favorable for accelerated economic growth;
•  Highlights the unprecedented ageing of the world’s 
population;
•  confirms the ongoing global increase in longevity and the 
narrowing gap between rich and poor countries, while also 
pointing to significant disparities in survival that persist 
across countries and regions;
•  Describes how international migration has become an 
important determinant of population growth and change  
in some parts of the world.
2015–2019 Surgical and Molecular 
Pathology (171644)
M 71008 F 100636
Clinical Cytopathology 2015–19
Non-vaginal 25025 M 8473 (34%) F 16552 (66)
Urine Cytology 30918 M 21794 (70,5) F 9124 (29,5)
crease the capabilities of biomedical science and tech-
nology to solve the related problems. For example, 5G 
technology will allow us to develop from information 
sharing to internet of things (IOT). Artificial intelli-
gence (AI) will greatly improve our ability to under-
stand and solve complex problems, while the break-
throughs in stem cell technologies and other geropro-
tective therapies will allow us to redefine healthy aging 
and to completely treat major diseases.
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it be associated with more illness, disability, and de-
pendency? Ageing will affect health care and social 
costs.
Global efforts are required to understand and find 
cures to prevent diseases like Alzheimer and frailty 
and to extend existing knowledge about the preven-
tion and treatment of heart disease, stroke, diabetes, 
and cancer.
The improvement in life expectancy is accompanied 
by the rise in chronic non-communicable diseases 
such as heart disease, diabetes and cancer. They reflect 
changes in lifestyle and diet and ageing. The economic 
and societal costs of non-communicable diseases of 
this type rise sharply with age.
Ageing is characterised by a progressive degenera-
tion of the tissues that has a negative impact on the 
structure and function of vital organs. Loss of physio-
logical integrity, a reduced capacity to respond to envi-
ronmental stimuli with age contribute to increased 
risk of disease and death. Ageing is among the most 
important known risk factors for most chronic diseas-
es. In general, it is determined by the interaction be-
tween injury and repair and the balance between cell 
death and cell replacement to maintain organ integrity. 
If cells die faster than they can be replaced, the remain-
ing cells need to respond to greater demands that can 
eventually lead to pathological changes and deteriora-
tion in cell health. Factors that modify the balance be-
tween cell death and replacement have considerable 
impact on the ageing process.
One common factor underlying the process of age-
ing is the accumulation of molecular damage and age-
ing may be considered to result from the accumulation 
of cellular damage, consequent changes in gene ex-
pression and epigenetic factors related to DNA dam-
age, and structural modifications of the DNA such as 
telomere shortening. Thus, ageing is influenced by the 
interaction of genetic and environmental factors. Two 
main theories of ageing are the free radical theory and 
the replicative senescence theory.
Evidence is accumulating that an optimal amount of 
radical oxygen species (ROS) are required for ageing. 
They can trigger proliferative and survival signals in 
response to physiological and stress signals. With age-
ing, levels of ROS increase in an attempt to maintain 
survival until they reach a level where they enhance 
age-related damage. ROS can also be formed by exog-
enous processes such as irradiation, environmental 
pollutants and inflammation, and normal cell metabo-
lism. Free radicals can accelerate replicative senes-
cence via shortening of telomeres, activate inflamma-
tory redox-sensitive transcription factors like nuclear 
factor-kB (NF-kB) that regulate transcription of genes 
encoding pro-inflammatory cytokines and induce 
DNA damage. Chronic inflammation, characterised 
by higher levels of pro-inflammatory cytokines and 
the infiltration of inflammatory cells into tissues, is a 
feature of ageing and most age-related diseases includ-
ing COPD, cardiovascular disease, osteoporosis, rheu-
matoid arthritis, cataract and Alzheimer’s disease.
The other theory of ageing is the replicative senes-
cence theory based on the fact that with every cell divi-
sion there is incomplete duplication of the telomeres at 
the ends of chromosomes containing 1–5 kb of 
(TTAGGG) repeats that protect DNA against degrada-
tion and recombination, thus supporting chromosom-
al stability. In most somatic cells telomeres shorten 
with every cell cycle since replicative DNA polymer-
ases lack the capacity to completely replicate the ter-
minal ends of linear DNA molecules, which is a prop-
erty of the specialised DNA polymerase known as 
telomerase. Most mammalian somatic cells do not ex-
press telomerase which leads to loss of telomere pro-
tective sequences at the ends of chromosomes. This is 
a result of the replication history, but also of a number 
of factors, such as cumulative oxidative stress and 
chronic inflammation, acting on progenitor cells. Suc-
cessive cell divisions result in telomere shortening of 
chromosomes until cells are no longer capable of di-
viding. Therefore, the balance between cell death and 
cell replication is affected and defence, maintenance 
and repair of the body becomes increasingly impaired. 
Telomere length is considered as a measure of biologi-
cal rather than chronological age or as a biomarker of 
somatic redundancy that is the body’s capacity to ab-
sorb damage. There is a strong relationship between 
short telomeres and the risk of mortality.
To conclude, understanding the mechanisms of age-
ing may provide a novel target for the treatment of this 
condition.
R e f e R e n c e
1. Suzman R, Beard J. Global health and aging. NIA, NIH, WHO. 
Public. 11-7737, 2011
2. Atella V, Piano Mortari A, Kopinska J et al. Trends in age-relat-
ed disease burden and healthcare utilization. Aging Cell 2019; 
18: e12861
3. Scott Kehler D. Age-related disease burden as a measure of 
population ageing. Lancet Public Health 4, 2019: e123–124
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A1-O1
The Joint Programme  
for Neurodegenerative Diseases 
(JPND), Towards a Globally 
Shared Brain Health
Philippe Amouyel
JPND – Inserm – Fondation Alzheimer – Lille University, France
The Joint Programming Initiative was originally cre-
ated as a Member States-led initiative in Europe. It 
aims to address “grand challenges” to the EU and glob-
al society by coordinating national research pro-
grammes to increase the impact and effectiveness of 
research efforts. Neurodegenerative diseases (ND) and 
dementia in particular, represent one of the world’s 
most pressing medical and societal challenges and the 
solutions are likely beyond the scope and resources of 
any single country. JPND aims to find causes, develop 
cures and identify better ways of caring for people with 
neurodegenerative diseases. Although JPND was orig-
inally a European initiative, it has since then gone 
global, with 30 countries participating today. Since its 
creation, JPND has raised more than €200 million for 
ND research. The tremendous progress of medicine in 
the last 50 years has led to a huge increase in total life 
expectancy for each of us. However, longer life expec-
tancy without disability is greatly dependent upon our 
brain health: neurodegenerative diseases and demen-
tia affect one third of the aging populations over 85 
years of age, mental health disorders including addic-
tions affect 12% of the entire population and neurode-
velopmental disorders affect 15% of children. This 
problem will only get worse as the European and glob-
al population inexorably ages. Together with JPND, 
several large European Commission (EC) initiatives 
have been established in Europe, to collectively face 
these huge challenges, namely: NEURON, an ERANET 
in the other fields of brain health and the Human Brain 
Project, an EC research flagship. These initiatives have 
addressed research questions related to determinants 
of mental health (from depression to addictions and 
compulsive disorders), neurodegenerative diseases 
(from Alzheimer’s disease and Parkinson’s disease to 
related disorders) and neurodevelopmental disorders 
(disturbance of the development of the central ner-
vous system). Since last year, all three initiatives have 
begun discussions in the context of EBRA (European 
Brain Research Area), to find operational synergies 
and identify gap. All these three initiatives have now 
acquired invaluable experience and trust. Strongly 
supported by the EC and Member States, the initia-
tives encompass significant non-European interna-
tional partners. This has allowed for the development 
of a unique holistic view of the European Brain Health 
research. By integrating such cutting-edge research 
dynamics and initiating an active translational mo-
mentum, the way for a powerful innovative force ready 
to consolidate an ambitious partnership on Brain 
Health in Horizon Europe is paved.
A1-O2
Healthy Ageing in Men:  
How to Prevent Andropausal 
Syndrome?
Davor Ježek
Center of Excellence in Reproductive and Regenerative Medicine, School of Medicine, 
University of Zagreb, Croatia
Department of Histology and Embryology, School of Medicine, University of Zagreb, 
Croatia
The advanced age in men is connected to an array of 
health disorders that bring significant pressure on 
public health system. The main androgen in men, tes-
tosterone, tends to decrease by 1–2% per year after age 
of 40. According to the European Male Ageing Study, 
there is a significant prevalence of low androgens lev-
els (also known as “biochemical hypogonadism”) in 
aging men (40 – 79 years old); it is estimated to be 
23.3%. Reduced serum levels of testosterone can occur 
in both young and aging men. A significant decline in 
serum testosterone levels affects about 5 million men 
in USA, including 20%–50% of men over age 60. Other 
men who also present themselves with biochemical 
hypogonadism include those with sickle cell disease 
and spinal cord injury, hypogonadotropic hypogonad-
ism and primary testicular deficiency (primary hypo-
gonadism). However, majority of men with biochemi-
cal hypogonadism remain asymptomatic. Those who 
became symptomatic have broad spectrum of symp-
toms such as sexual dysfunction, metabolic disorders, 
overall dissatisfaction, as well as increasing emotional 
disturbances, moodiness, irritability, nervousness, de-
pression, fatigability, poor concentration, and deterio-
rating memory. All these symptoms are known as an-
dropausal syndrome. The main source of androgens in 
men are Leydig cells (>95% of testosterone produc-
tion). The rest of androgens are coming from the cor-
tex of suprarenal gland. In ageing men, Leydig cells 
seem to be less responsive to LH. Morevoer, this less 
responsiveness is often combined with other comor-
bidities such as metabolic syndrome, prediabetes and 
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diabetes, adiposity, cardiovascular problems, psycho-
logical disturbances (including dementia) and osteo-
porosis. Early recognition/screening programme of 
biochemical hypogonadism and andropausal syn-
drome in particular is critical in prevention of ageing 
symptoms mentioned above. The screening pro-
gramme may, among other parameters, include mea-
surements of total testosterone, free testosterone, de-
hydroepiandrosterone sulfate, and insulin-like growth 
factor 1. Androgen substitution therapy is one of the 
strategies how to fight andropausal syndrome.
A1-O3
Representative Model of Sporadic 
Alzheimer’s Disease and Its Use 
for Testing of Novel Therapeutic 
Strategies
Melita Šalković-Petrišić
Department of Pharmacology, School of Medicine, University of Zagreb, Croatia
Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Croatia
Ageing has imposed itself as a major risk factor in 
development of Alzheimer’s disease, particularly its 
sporadic form (sAD) which affects about 13% and 50% 
of patients aged >65 and >85 years, respectively. sAD is 
an incurable neurodegenerative disorder character-
ized by a progressive memory loss. It presents the most 
common cause of dementia affecting over 45 million 
people world-wide. Type 2 diabetes mellitus (T2DM) 
stands out as the most prominent age-related risk fac-
tor associated with sAD. Recent data suggests that 
sAD and T2DM can be considered as “syndrome of 
accelerated ageing” so elucidation of their common 
pathophysiology, and their prevention and treatment 
is of utmost importance for healthier ageing. Brain in-
sulin resistance (BRI) has emerged as a potential link 
between metabolic and cognitive dysfunction shared 
by sAD, T2DM and aging, in addition to oxidative 
stress and neuroinflammation. Thus, approved antidi-
abetic drugs like glucagon-like peptide-1 (GLP-1) re-
ceptor agonists are now being tested as suitable candi-
dates for sAD treatment. Ineffectiveness of the avail-
able symptomatic AD therapy and a failure of pharma 
industry in new AD drug development imposed an 
urgent need for a successful disease-modifying drug 
which should be tested in a representative sAD animal 
model. We have developed a non-transgenic rat sAD 
model based on the administration of streptozotocin 
(a compound which following a peripheral adminis-
tration of high dose induces diabetes mellitus) into the 
lateral brain ventricles (STZ-icv model). The model 
develops BIR (but not systemic diabetes) and our re-
search on its further characterization has demonstrat-
ed that the model eventually manifests many sAD-like 
behavioral (cognitive decline), neuropathological 
(amyloid ß/tau protein accumulation, oxidative stress, 
neuroinflammation), and cerebral structural (cortical 
thickness) and metabolic (glucose hypometabolism) 
characteristics. We use the STZ-icv rat model also as a 
platform to test novel therapeutic strategies in sAD 
treatment. Our current research explores stimulation 
of the endogenous GLP-1 by oral galactose with pre-
liminary results indicating that 2-month daily expo-
sure to oral galactose initiated in the early sAD-like 
stage improves impaired learning and memory func-
tions in STZ-icv treated rats accompanied by normal-
ization of brain glucose hypometabolism, increments 
in active plasma GLP-1 levels and increased expres-
sion of GLP-1 receptors in the brain. Determination of 
the therapeutic potential and limitations of this novel 
nutrient-based therapeutic approach in sAD treat-
ment is in progress. Funded by the Croatian Science 
Foundation IP-2014-09-4639, IP-2018-01-8938.
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A1-P1
Diagnostic, Prognostic  
and Predictive Biomarker Testing 
in Pathology – Needs and 
Opportunities in Solid Tumour 
Oncology of the Ageing Society
Sven Seiwerth
Department of Pathology, School of Medicine, University of Zagreb, Croatia
Neoplastic disease are, having some exceptions in 
the field of hemato- and neuropathology, by far more 
common in older people. The theoretical basis of this 
is wide, not always will defined by clearly including 
passing of time as one of the key factors. Simply being 
around for a longer time period makes us more ex-
posed to intrinsic and extrinsic stressors, meanwhile 
diminishing our defense mechanisms and capacity. In 
today’s medicine the recently widely opened field of 
new drugs enabling more directed, „individualized“ 
therapy is currently representing the backbone of a 
rapidly evolving success in fighting cancer. In most in-
stances these „smart“ drugs need „smart“ diagnostic 
tools in order to better define targets for tailored thera-
peutic approach. Despite the fact that currently most 
of this happens in the field of genetics, the story begun 
with hormones – ER i PgR in breast cancer being the 
first targets of a directed therapy. The next step was 
also breast cancer – HER-2 (already an amplified gene 
receptor from the EGFR family). After a relatively si-
lent period (in which we got the c-kit mutated positive 
GIST as a target of imatinib mesylate) an explosion 
happened. In the last ten years we are witnessing inclu-
sion of more and more mainly genetically targeted 
therapy – RAS in metastatic colon cancer and EGFR 
TKI’s leading the group, followed by ALK, ROS and 
MET in lung cancer, BRAF in melanoma (and lung 
cancer) and BRCA in triple negative breast and serous 
ovarian cancer. As of last year the 1p/19q co-deletion 
is a WHO recognized biomarker in oligodendrogio-
ma. Meanwhile especially in soft tissue and bone tu-
mors a wide array of diagnostic biomarkers is evolv-
ing, with so far litle or no therapeutic consequences. 
Ever sophisticate technologies are today opening 
widely the field of multigene testing, meanwhile also 
opening the question of rationalizing diagnostic ef-
forts. Commercial suppliers introducing several stra-
tegic, financial and ethical questions often offer this 
type of testing an open a wide field for discussion. 
Should we test everyone? Should we diagnose genetic 
changes with not known targets? Should we invest 
more into treating known targets with known drugs or 
should we try to come to the genetic basis of every ma-
lignancy, despite the costs and with doubtful rationale? 
Can we (financially) treat all our patients with the 
most high-end therapy? We have many difficult ques-
tions to answer but live one of the most exciting peri-
ods in modern oncology.
A1-P2
Early Diagnosis of Hidden 
Hearing Loss as the Prevention  
of Hearing Impairment in Older 
Working-age Population
Roko Žaja1, Hana Brborović1, Mihael Ries2, Milan Milošević1
1  Department for Environmental Health, Occupational and Sports Medicine,  
Andrija Štampar School of Public Health, School of Medicine, University of Zagreb, 
Croatia
2  University Hospital Centre Sestre Milosrdnice, School of Medicine, University of Zagreb, 
Croatia
Introduction. Noise-induced hearing loss (NIHL) is 
preceded by a cochlear synaptopathy and a conse-
quential hidden hearing loss (HHL) with no shift in 
hearing threshold. In middle-aged working-age popu-
lation, HHL or NIHL are exacerbated by the onset of 
age related-hearing loss. The hearing threshold usually 
shifts bilaterally at high frequencies after years of ex-
posure to noise intensity levels greater than 87 dB(A) 
during the 8-hour working day. The objective was to 
analyse the applicability of existing procedures in the 
diagnosis of HHL in order to prevent further noise 
 exposure and the following hearing impairment. 
Methods. Literature review was made in PubMed Da-
tabase using keywords: age-related hearing loss; noise-
induced hearing loss; hidden hearing loss. We did our 
research on studies published in the past 20 years. 
 Results. As a direct measure of the cochlear synaptop-
athy degree, some studies suggest the reduction in the 
auditory brainstem response wave I amplitude and 
others an increase in the ratio of summating and ac-
tion potential. However, wave I amplitude is highly 
variable in humans, and it is not completely clear how 
loss of cochlear synapses leads to an increase of sum-
mating potential. Loss of synapses was also found in 
autopsy material of otologically healthy persons, sug-
gesting that this synaptopathy may be independently 
mediated by aging. On the other hand, prolonged 
noise exposure at the workplace increases sympathetic 
activity and causes an increase of the cortisol concen-
tration in the blood. This increase is consistent with 
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the increase of salivary cortisol and salivary cortisone 
concentrations easily measured during the workday. 
conclusion. Auditory and extra-auditory noise effects 
should be observed simultaneously and measured 
non-invasively. Except standard audiological test bat-
tery, electrophysiological results, such as auditory 
brainstem response findings should be also taken into 
account and supplemented by psychometric and hor-
monal findings. With such diagnosis and with evi-
dence of excessive noise exposure, it is important to 
find technical solutions or restrict the work in such 
hazardous working environment and to advise work-
ers on the use of personal protective equipment with 
regular supervision. Further studies should explain 
the relative contribution of noise exposure and age, re-
spectively, to the development of cochlear synaptopa-
thy. This kind of approach to the early diagnosis could 
significantly reduce the risk of developing severe hear-
ing loss in older age and eventually increase the work 
capacity of noise-exposed workers.
Session A2: Molecular Basis of Ageing
Invited lecture
A2-I
Lifespan and Health Span in Mice: 
Mechanisms and Interventions
Dan Ehninger
German Centre for Neurodegenerative Diseases, Germany
Aging is a major risk factor for a large number of 
adult-onset disorders, including neurodegenerative 
 disorders, cardiovascular diseases and cancers, and is 
associated with a broad range of functional impair-
ments. Targeting aging processes with suitable pharma-
R e f e R e n c e s
1. Xie K, Ryan DP, Pearson BL, et al. Epigenetic alterations in lon-
gevity regulators, reduced lifespan, and exacerbated aging-re-
lated pathology in old father offspring mice. Proc Natl Acad 
Sci USA 2018;115(10):E2348–E2357.
2. Xie K, Neff F, Markert A, et al. Every-other-day feeding ex-
tends lifespan but fails to delay many symptoms of aging in 
mice. Nat Commun 2017;8(1):155.
3. Neff F, Flores-Dominguez D, Ryan DP, et al. Rapamycin extends 
lifespan but has limited effects on aging in mice. J Clin Invest 
2013;123(8):3272–91.
cological or dietary interventions could potentially rep-
resent a powerful inroad for the development of preven-
tatives or treatments for aging-associated disorders.
A large number of genes and pathways have been 
identified that extend lifespan in invertebrates. In 
some cases, analogous manipulations have been shown 
to also extend lifespan in mammals. Relatively under-
explored, however, is the question to what degree these 
lifespan-extending manipulations also slow mamma-
lian aging rates and promote overall healthy aging in 
mammals on the level of organs and tissues. Large-
scale analyses of aging-associated molecular, cellular, 
physiological and histopathological changes constitute 
an effective approach to identify and dissect possible 
treatment or prevention effects in animal models.
This presentation will cover data detailing how aging 
phenotypes, in a range of physiological systems, unfold 
across the lifespan of mice and humans. Moreover, I will 
share data examining how key biological processes im-
plicated in aging change over the murine lifespan. Fi-
nally, I will discuss the question to what extent lifespan-
extending manipulations slow mammalian aging rates 
and promote overall healthy aging in mammals on the 
level of organs and tissues. The line of work discussed 
exemplifies a research approach that is key for providing 
a foundation for translational opportunities that link 
the biology of aging to new medicines for the preven-
tion of a broad range of age-related diseases.
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A2-O1
High Capability of Human 
Prefrontal Cortex Microcircuitry 
to Maintain Its Structure During 
Ageing
Zdravko Petanjek, Ana Hladnik, Ivana Bičanić, Domagoj Džaja,  
Dora Sedmak, Ivan Banovac, Andrea Blažević, Sanja Damopil
Department of Anatomy and Clinical Anatomy, School of Medicine, University of Zagreb
We analyzed changes in dendritic morphology and 
spine density on associative layer IIIc cortical project-
ing neurons and large layer V subcortical projecting 
pyramidal neurons to establish age-related changes 
within microcircuitries of the human prefrontal cortex 
(Brodmann area 9). Postmortem human brain tissue 
of adults was processed using the rapid Golgi method 
in two age groups: 38 – 64 years (n = 8) and 72 – 91 
years, (n = 7). Neuropathological findings were unre-
markable in all analyzed brain specimens. From each 
layer, the basal dendritic arbor and side dendritic 
branches from 10 – 15 well-impregnated pyramidal 
neurons per subject were three-dimensionally recon-
structed using Neurolucida software. Soma size, total 
dendritic length, total segment number, individual 
segment length and spine density were quantitatively 
analyzed. Regarding layer V neurons, no significant 
differences were observed between adults and the el-
derly, either for dendritic morphology or for the spine 
density. The interindividual differences in the elderly 
group were however higher than in adults. Regarding 
associative layer IIIc pyramidal neurons, the mean val-
ues of spine density, on both side branches and basal 
dendrites, were 20–25% lower in the elderly than in 
adults (p = 0.07). In two aged cases the spine density 
was around mean level of adult and in the remaining 
aged subjects values were lower than in all adult sub-
jects. These data show that the dendritic morphology 
and synaptic connectivity of the major classes of 
 principal neurons in higher order associative areas 
are largely preserved in aging, while the connectivity 
of associative cortico-cortical layers is more prone to 
regression.
A2-O2
Antioxidant Ameliorated Negative 
Impact of a DNA-Demethylating 
Agent on Placental Growth  
and Morphology of Aged Preterm 
Placentas
Nikola Sobočan1,2, Ana Katušić-Bojanac1,3, Nino Sinčić1,3,  
Marta Himelreich-Perić1,3, Jure Krasić1,3, Željka Majić1,  
Gordana Jurić-Lekić1,4, Ljiljana Šerman1,3, Maja Vlahović1,3,  
Andreja Marić5, Davor Ježek1,4, Floriana Bulić-Jakuš1,3
1  Center of Excellence in Reproductive and Regenerative Medicine, School of Medicine, 
University of Zagreb, Croatia
2  Department of Gastroenterology, University Hospital Merkur, School of Medicine, 
University of Zagreb, Croatia
3  Department of Medical Biology, School of Medicine, University of Zagreb, Croatia
4  Department of Histology and Embryology, School of Medicine, University of Zagreb, 
Croatia
5 Department of Internal Medicine, County Hospital Čakovec, Croatia
Introduction and Objectives. We showed that a 
DNA-demethylating agent/ epigenetic drug 5-azacyti-
dine (5azaC) used in treatment of human malignan-
cies is a teratogen that impaired development of both 
embryos and placentas in treated rat dams, while pre-
treatment with the antioxidant N–tert– Butyl–α–
phenylnitron (PBN) improved development of rat fe-
tuses. We now investigated whether PBN could im-
prove the placental development and aging. Methods. 
On the 12th and 13th days of gestation, Fisher rat 
dams were pretreated by an i.v. injection of PBN (40 
mg/kg) and one hour later by an i.p. injection of 5azaC 
(5mg/kg) or only with 5azaC. Controls were treated 
only with PBN or were sham- treated. On the 15th and 
20th days of gestation placentas were weighted. Immu-
nohistochemical signals of the Proliferating Cell Nu-
clear Antigen (PCNA) and markers of oxidative/nitro-
sative processes (8-oxoDG and nitrotyrosine, respec-
tively) were stereologically quantified by the numeri-
cal density (Nv). Apoptotic index was calculated and 
DNA-methylation was assessed by pyrosequencing. 
All results were statistically evaluated. Results.Pre-
treatment with PBN ameliorated placental morpholo-
gy of aged preterm 20-days-old placentas which was 
disturbed by 5azaC. PBN-pretreatment significantly 
improved weight of 15- and 20-days old placentas. In 
aged preterm placentas apoptotic index was signifi-
cantly lower in samples pretreated with PBN than in 
only 5azaC treated, and that was associated with a sig-
nificantly lower Nv of 8-oxoDG and nitrotyrosine. Nv 
for the cell proliferation marker (PCNA) was signifi-
cantly lower in all treated with 5zaC than in controls. 
conclusions. Pretreatment with the antioxidant PBN 
ameliorated negative impact of the DNA-demethylat-
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ing epigenetic drug on the aged, preterm placentas. 
Because DNA demethylation causing oxidative stress 
might also be of importance for placental premature 
aging during human gestation, we propose further in-
vestigation of the antioxidant PBN activity.
A2-O3
Glycans as Biomarkers  
and Functional Effectors of Age 
and Age-Related Diseases
Gordan Lauc
Faculty of Pharmacy and Biochemistry, University of Zagreb, Croatia
The majority of proteins that evolved the after ap-
pearance of multicellular life are glycosylated and gly-
cans significantly affect structure and function of these 
proteins. However, due to structural complexity of gly-
cans and the absence of a direct genetic template, the 
analysis of protein glycosylation is much more compli-
cated than the analysis of DNA or proteins. Conse-
quently, the knowledge about the importance of indi-
vidual variation in glycans for both normal physiolog-
ical processes and diseases is still limited. In the last 
few years it is becoming increasingly clear that varia-
tions in a DNA sequence are only a beginning of the 
understanding of complex human diseases. Genetic 
polymorphisms have to be put in the context of com-
plex biology of life and a more elaborate approach that 
combines different ‘omics phenotypes is needed to un-
derstand disease mechanisms and perform patient 
stratification that transcends genomics. Glycomics, as 
by far the most complex posttranslational modifica-
tion, has an immense potential in this respect, which is 
only beginning to be investigated. By generating gly-
comic data for over 100,000 individuals from some of 
the best characterized clinical and epidemiological co-
horts we enabled glycomics to meet other ‘omics. The 
analysis of this rich gold mind is painting a picture of a 
very complex genetic and epigenetic regulation of gly-
cosylation that fine tunes protein activity in multiple 
biological systems and also contributes to ageing at 
the molecular level. In particular, the evidence is 
 accumulating that in cardiometabolic diseases chang-
es in glycosylation are not only biomarkers, but func-




Senescent Phenotype  
and Disturbances in Autophagy  
in ATM-Deficient Neural 
Precursor Cells
Piotr Sunderland1, Justyna Augustyniak2,  
Leonora Buzanska2, Ewa Sikora1
1  Laboratory of Molecular Bases of Ageing, Nencki Institute of Experimental Biology, 
Polish Academy of Sciences, Warsaw, Poland
2  Department of Stem Cell Bioengineering, Mossakowski Medical Research Centre  
Polish Academy of Sciences, Warsaw, Poland
ATM is a kinase involved in DNA damage response 
(DDR), regulation of response to oxidative stress, au-
tophagy and mitophagy. Mutations in the ATM gene 
in humans result in ataxia-telangiectasia disease (A-T) 
characterized by a variety of symptoms with neurode-
generation and premature ageing among them. In this 
study, we have focused on the process of senescence in 
A-T cells. Given that brain is one of the most affected 
organs in A-T, we turned our attention to neural pro-
genitor cells (NPCs) derived from A-T reprogrammed 
fibroblasts. We observed that A-T NPCs obtained 
through neural differentiation of iPSCs in 5% oxygen 
possessed some features of senescence including in-
creased activity of SA-β-gal and secretion of IL6 and 
IL8 in comparison to control NPCs. This phenotype of 
A-T NPC was accompanied by elevated oxidative 
stress resulting in 4-HNE protein modification. A-T 
NPCs exhibited symptoms of impaired autophagy and 
mitophagy with lack of response to chloroquine treat-
ment. Additional sources of oxidative stress like in-
creased oxygen concentration (20%) and H2O2 re-
spectively aggravated the phenotype of senescence and 
additionally disturbed the process of mitophagy. The 
latter was confirmed by transcriptional analysis of sev-
eral mitophagy-associated genes. In both cases only 
A-T NPCs reacted to the treatment. We conclude that 
oxidative stress may be responsible for the phenotype 
of senescence and impairment of autophagy in A-T 
NPCs. Our results point to senescent A-T cells as a po-
tential therapeutic target in this disease.
Supported by grant no. 2012/07/B/ NZ3/02180 from 
National Science Centre to ES and statutory funds to 
Mossakowski Medical Rearch Centre to LB.
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A3-I
Idiopathic Rapid Eye Movement 
Behaviour Disorder
Ivana Rosenzweig
King’s College, London, UK
Idiopathic rapid eye movement (REM) sleep behav-
ior disorder (iRBD) is increasingly recognised as an 
important precursor disease state of alpha-synucle-
inopathies. This parasomnia is characterized by a his-
tory of recurrent nocturnal dream enactment behav-
iour, loss of skeletal muscle atonia, and increased pha-
sic muscle activity during REM sleep. Neuroimaging 
studies of striatal dopamine transporter uptake tracer 
signalling suggest increasing dopaminergic deficit 
across the continuum of the alpha-synucleinopathies, 
with early sleep dysfunction suggestive of early cau-
date dysfunction. We will discuss the implication of 
utilising this window of the opportunity in the disease 
process to intervene, and to potentially abort, further 
development of neurodegenerative process.
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2. Chersi F, Burgess N. The Cognitive Architecture of Spatial 
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Obstructive Sleep Apnoea 
Assessment in the Elderly
Renata Pecotić, Linda Lušić Kalcina, Ivana Pavlinac Dodig,  
Maja Valić, Zoran Đogaš
Department of Neuroscience, University of Split School of Medicine, Split, Croatia
Obstructive sleep apnea (OSA) is one of the most 
common sleep related breathing disorders character-
ized by repetitive episodes of complete (apnea) or par-
tial (hypopnea) cessations of breathing due to obstruc-
tions in upper airways followed by significant oxygen 
desaturations. Chronic intermittent hypoxia com-
bined with frequent arousals during sleep results with 
dysfunction of autonomic nervous system that pro-
motes development of hypertension, glucose intoler-
ance, cardiovascular and cerebrovascular disorder. 
Prevalence of OSA tends to increase due to increased 
prevalence of obesity and ageing of the population. 
OSA has negative impact on health and quality of life 
and aggravates ageing and ageing-related diseases and 
comorbidities. As such, OSA should be adequately 
screened in order to apply adequate medical care espe-
cially in the elderly. Different clinical models have 
been developed to evaluate patients who are at risk for 
OSA. Usually we use screening questionnaires such as 
STOP (Snoring, Tiredness, Observed apnea, and high 
blood Pressure) and STOP-BANG (STOP + Body 
mass, Age, Neck circumference, Gender), which are 
concise and easy-to-use in daily clinical practice. In a 
large sample of 4136 subjects from the area of Split and 
Split-Dalmatia County, screened with STOP question-
naire we found that the risk for OSA steadily increases 
with age. Particularly vulnerable was the group of men 
aged 41–50 years, in whom the risk of OSA and associ-
ated excessive daytime sleepiness was significantly 
more pronounced compared to female respondents of 
the same age. In older population (> 60) we found 
highest risk for OSA, with women becoming at risk for 
OSA as much as men (55% vs. 51%). When we investi-
gated the validity of OSA screening questionnaires 
against objective diagnostic polysomnography and 
polygraphy procedures, the STOP and STOP-BANG 
questionnaire revealed similarly high sensitivity (0.87), 
specificity (0.54) and positive predictive value (0.90) in 
the detection of OSA when applied in a population of 
Session A3: Ischemic, hypoxic, hemorrhagic brain disorders & ageing
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sleep clinics patients in Split Sleep Medicine Center. 
This indicates that the prevalence in general popula-
tion is really high, and is strongly associated with age-
ing. Also, some recent publications indicate that 
screening for OSA among elderly were prevalence of 
OSA is as high as 83% requires modifications. Further 
validation studies of applied questionnaires designed 
specifically for the elderly population are necessary in 
order to reduce negative effects on health and avoid 
unnecessary and costly OSA diagnostic procedures.
A3-O2
I Forgot to Sleep
Domagoj Vidović1, Ana Marija Šantić1, Marina Mioč1,  
Ana Jadrijević-Tomas1, Hrvoje Grbavac1, Petrana Brečić1,2
Center for Sleep Disorders, University Psychiatric Hospital Vrapče, Zagreb, Croatia
School of Medicine, University of Zagreb, Croatia
Sleep is essential for healthy living and relationship 
between dementia and insomnia is a complex one. 
Both conditions are highly prevalent among demented 
patients and sleep disorders, with insomnia in first 
place, makes things even more difficult to treat. Con-
temporary view on insomnia among demented pa-
tients and pathways to care will be explained. Non-
pharmacological, often neglected methods should be 
tried out first, with somatic conditions, dose titration 
and side effects of medication being biggest obstacles 
in psychopharmacology. Personalized medicine ap-
proach regarding stage of dementia, housing condi-
tions, caregiver’s possibility and general medical con-
dition should be implemented in treatment.
A3-O3
REM Behaviour Disorder and 
Neurodegenerative Disorders
Ana Marija Šantić
Center for Sleep Disorders, University Psychiatric Hospital Vrapče, Zagreb, Croatia
Rapid eye movement (REM) sleep behavior disor-
der (RBD) is a sleep disorder characterized by enact-
ing one’s dreams during the REM sleep, with most of 
the dreams being violent or aggressive, so that patients 
often complaint to hurt themselves or bed partner 
during these episodes. Prevalence of RBD, based on 
population, is 0.38–2.01 %, but much higher in pa-
tients with neurodegenerative disorders, especially 
synucleinopathies. RBD may herald the emergence of 
synucleinopathies by decades, such that it may be used 
as an effective early marker of neurodegenerative dis-
orders, precisely synucleinopathies. Lesion or dys-
function in REM sleep and motor control circuitry in 
pontomedullary structures cause RBD phenomenolo-
gy, and degeneration of these structures might explain 
the presence of RBD years or even decades before the 
onset of Parkinson’s disease (PD), dementia with lewy 
bodies (DLD) and multiple system atrophy (MSA). 
RBD occurs in 30–50 % of patients with sporadic PD, 
preceding the onset of parkinsonism by several years 
in about 20 % of them. The majority of patients with 
MSA have RBD, recent meta-analysis reported preva-
lence of clinically suspected RBD in MSA of 73 %, 
while polysomnographically confirmed RBD was up 
to 88 %. RBD is recognized as one of the core features 
of DLB and may occur either in advance or simultane-
ously with the onset of DLB. The prevalence of RBD in 
DLB is up to 76 %. On polysomnography RBD is pre-
sented as repeated episodes of vocalization and/or 
complex motor behaviors during REM sleep which 
reflects the loss of normally present atonia in REM (i.e. 
REM sleep without atonia – RSWA). Sometimes when 
typical behaviors are not seen in polysomnography but 
are known to exist based on medical hystory, even the 
presence of RSWA is sufficient to diagnose patients 
with RBD. In cases of idiopathic RBD, precisely those 
patients who at the time of diagnosis don’t exhibit clin-
ical signs of Parkinson disease, DLB or MSA, the treat-
ment is mainly symptomatic and is based on lowering 
motor activity in sleep, promoting sleep contiuity and 
readdressing sleep desynchronization. Clonazepam 
and melatonin are main substances used in treatment. 
While there is not known effective neuroprotective 
substance yet, it is important to recognize these para-
somnias as they can precede typical motor and cogni-
tive symptoms of neurodegenerative diseases by many 
years and as such demmand regular neurological and 
neuropsychological follow-up.
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A3-P1
Predictors of Sleep Quality  
in Older Adults in Zagreb
Adrijana Košćec Bjelajac1, Jasminka Despot Lučanin2,  
Eva Anđela Delale3, Damir Lučanin4
1 Institute for Medical Research and Occupational Health, Zagreb, Croatia
2 Division of Psychology, Faculty of Croatian Studies, University of Zagreb, Croatia
3 Institute for Anthropological Research, Zagreb, Croatia
4 University of Applied Health Sciences, Zagreb, Croatia
The changes in sleep-wake process over the lifespan 
are well established. Epidemiological data show that 
50–65% of older adults report impaired sleep quality 
(SQ). This impairment can rather be attributed to 
health status and various psychosocial factors than to 
the aging process per se. The results of our previous 
study showed the expectedly impaired SQ in nursing 
home residents, best predicted by self-perceived health 
and functional ability. The aims of the current study 
were to examine SQ of older adults living in different 
arrangements and to examine factors contributing to 
their SQ. Participants were 334 older adults (73% fe-
males) from Zagreb. Half were the NH residents and 
half OH residents. Their dominant age was 78 years, 
varying between 69 and 100 years. All were ambula-
tory, without diagnosis of dementia. Trained inter-
viewers collected data individually, through structured 
interviews in nursing homes and in gerontology cen-
ter. Questionnaire comprised of general questions, 
questions to assess self-perceived health and standard-
ized scales to measure social participation, functional 
ability, life satisfaction, and SQ. SQ was assessed by the 
Pittsburgh Sleep Quality Index (PSQI). Our results 
showed PSQI score greater than 5, indicating poor SQ 
in 60% of older adults. In NH residents the percentage 
was higher than in OH residents (71% vs. 50%, p < 
.001). Selected set of predictors explained small but 
significant proportion of variance in PSQI score and 7 
domains. Predictors explained the highest proportion 
of variance in the use of sleep medication (22.6%) and 
subjective SQ (21%). Expectedly, women had poorer 
total PSQI, longer sleep latency and used more sleep 
medication than men. Older age significantly predict-
ed only the use of sleep medication, as was expected 
within this age range. Living in NH predicted worse 
PSQI, shorter sleep duration, less sleep efficiency, 
more use of sleep medication and poorer daytime 
functioning. Greater life satisfaction predicted better 
total PSQI, higher subjective SQ, longer sleep dura-
tion, shorter sleep latency, less sleep disturbances and 
less use of sleep medication. Poorer self-perceived 
health predicted poorer PSQI, worse subjective SQ, 
more sleep disturbances and more use of sleep medi-
cation while better functional ability predicted shorter 
sleep latency and better daytime functioning. Separate 
predictors’ analyses of NH and OH older adults are 
called for to enable tailoring preventive strategies ac-
cording to specific needs. Contribution of psychoso-
cial factors in SQ prediction in older age points to the 
necessity of investment in sleep hygiene education and 
psychosocial support, especially to NH residents.
A3-P2
Patient-Centred Care Based  
on Fog Computing Paradigm:  
A Case of Sleep Apnoea Detection
Ace Dimitrievski1, Saso Koceski2, Natasa Koceska2, Eftim Zdravevski1, 
Petre Lameski1, Hrvoje Belani3, Vladimir Trajkovik1
1  Faculty of Computer Science and Engineering, Ss. Cyril and Methodius University, 
Skopje, RN Macedonia
2 Faculty of Computer Science, University Goce Delčev, Stip, RN Macedonia
3 Ministry of Health, Zagreb, Croatia
Introduction and Objectives. Sleep apnea is medi-
cal condition that affects about 4% of the population 
and may cause various medical complications such as 
fatigue, hearth problems and elevated blood pressure, 
diabetes type II, metabolic syndrome and others. 
Nowadays, there is a huge demand for technology so-
lutions and new care models that will help in under-
standing patient’s needs and characteristics, facilitat-
ing treatment adherence and shared-decision making. 
Methods. This paper proposes a system and method-
ology based on fog computing paradigm to unobtru-
sively detect sleep apnea and to enable patients with 
sleep apnea and health care providers to be active par-
ticipants and collaborate in chronic disease manage-
ment. The methodology is based on findings that sleep 
apnea is accompanied by body or leg movement. 
Therefore, the proposed system uses non-invasive PIR 
and piezoelectric-based sensors placed under the mat-
tress. Data processing and sleep apnea detection is 
performed by machine learning algorithms on the 
edge nodes. Anonymized data are also sent to the cloud 
for further evaluation and assessment by medical ex-
perts and are used for model improvement. Results. In 
order to evaluate the proposed system and methodol-
ogy, an experiment for continuous monitoring of a 
single person over a period of 8 hours was conducted. 
Signals obtained from PIR and bed sensors were seg-
mented and signal features were extracted. Depending 
on the window length 250 to 270 features in total were 
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generated, and then reduced to 32 by discarding those 
with low importance or high data drift sensitivity. Four 
machine learning algorithms for sleep apnea detection 
were applied on the obtained feature set and the results 
were compared. The accuracy of the different classifi-
ers based on different sliding window configurations 
was analyzed. It was found that, as windows length in-
creases, the accuracy increases too. When using win-
dows of 5 seconds the accuracy was 80%, when the 
window length was increased to 10 seconds, the accu-
racy raised to around 90%, and for 20 seconds win-
dows, the accuracy further improved to above 95%. 
conclusions. The use of novel technology, like unob-
trusive sensors and fog computing, can improve the 
patient-centered care for patients with sleep apnea. 
The flexibility of the fog architecture enables better 
placement of computing and network resources. The 
fact that accuracy is increasing for larger window 
length is an important discovery. It can be used for de-
sign of a system that makes several predictions at the 
same time. In this proof the concept of the proposed 
system architecture we have conducted experiment 
with only 3 patients, which has to be increased.
A3-P3
Teatment of Sleep Disorders  
in Elderly
Marina Mioč
Center for Sleep Disorders, University Psychiatric Hospital Vrapče, Zagreb, Croatia
Changes in sleep architecture and duration are a 
part of a normal ageing. It is crucial not to mistake 
sleep disorders for physiologic changes in sleep-awake 
patterns in elderly because untreated sleep disturbanc-
es may predict the risk of dementia and they are asso-
ciated with worse late-life cognition.
Frequent sleep disorders in elderly include: insom-
nia, obstructive sleep apnoea (OSA), restless legs syn-
drome (RLS), circadian rhythm sleep disorder with 
phase advance and REM behaviour disorder (RBD). 
Treatment of these disorders include different phar-
macological measures and non-pharmacological ac-
tivities which include stimulus control, sleep hygiene 
education, relaxation therapy, cognitive behavioural 
therapy, bright light therapy and CPAP for OSA.
Pharmacologic treatment of sleep disorders should 
be taken with extreme care in older individuals. There 
is a greater risk of side effect even at lower doses and 
interactions with concomitant medications. Benzodi-
azepines and nonbenzodiazepine receptor agonists 
often used for treating insomnia can lead to tolerance, 
dependence, rebound insomnia, daytime sedation, 
motor incoordination, cognitive impairment and in-
creased risk of falls in institutionalized older individu-
al. Because of these adverse effects and superior re-
sponse seen in cognitive behavioural therapy, use of 
these drugs should be avoided in older individuals. To 
avoid similar adverse effects in treating RBD with 
clonazepam, alternative therapy with melatonin recep-
tor agonist is often used because it is safer and better 
tolerated. Treating of OSA has some different chal-
lenges. Very effective CPAP not only improves sleep 
quality and daytime sleepiness but adequate use of 
long‐term CPAP therapy improves cardiovascular out-
comes. The main problem of CPAP treatment in el-
derly is that studies show that CPAP adherence de-
creases as age increases, and it is particularly poor in 
patients aged >75 years. Individualized treatment and 
close monitoring could possibly improve compliance.
Sleep disorders are common problem in all age 
groups, particularly in elderly. If untreated they are as-
sociated with cognitive impairment so diagnosis and 
treatment of sleep disorders are of great importance 
for healthy ageing.
A3-P4
Obstructive Sleep Apnoea 
Aggravates Age-Associated Decline 
in Psychomotor Performance
Ivana Pavlinac Dodig, Linda Lušić Kalcina, Renata Pecotić,  
Maja Valić, Zoran Đogaš
Department for Neuroscience, Sleep Medicine Center,  
University of Split School of Medicine, Split, Croatia
Ageing is associated with a decrease in various cog-
nitive and psychomotor abilities as well as problem-
solving tasks, probably due to simultaneous structural 
and functional changes in specific brain regions, pre-
cisely in the frontal lobes. In our study assessment of 
the dynamic properties of the central nervous system 
has been performed with the computerized psycho-
motor testing device composed of numerous different 
tests using chronometric approach. In a large sample 
of 3420 subjects, we demonstrated that age positively 
correlated with the reaction times in tests of discrimi-
nation of the light signal position, complex psychomo-
tor coordination, and convergent thinking. Thus, our 
results support the concept of association of reduced 
cognitive and psychomotor abilities with the advanced 
age. The prevalence and severity of the obstructive 
sleep apnea (OSA) increase with advanced age. More-
over, the untreated OSA is associated with various age-
related disturbances, including decline in physiologi-
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cal and psychological performances. However, does 
OSA aggravate age-related cognitive and psychomotor 
decline and to what extent remains to be evaluated. In 
another study, on a total of 103 patients with moderate 
and severe OSA, we demonstrated that severe OSA 
impaired the speed of perception, convergent, and op-
erative thinking, indicated by prolonged reaction 
times in the perception of visual stimulus, solving sim-
ple arithmetic operations, and in tasks requiring psy-
chomotor coordination of the upper and lower limbs. 
Furthermore, severe OSA decreased the stability to-
ward the end of the test, indicating that OSA patients 
get considerably slower toward the end of tasks com-
pared to control participants of the same age. Finally, 
in the test of the complex psychomotor coordination 
of the computerized psychomotor testing device, OSA 
patients had significantly more pronounced prolonga-
tion of the reaction times in comparison to the control 
subjects of the same age. In conclusion, both ageing 
and OSA are associated with the decline in cognitive 
and psychomotor performance. However, the impair-
ments in complex psychomotor coordination of the 
limbs are more pronounced in apneic patients sup-
porting the conclusion that OSA aggravates age-relat-
ed decline in psychomotor performance.
A3-P5
Sleeping 8.5 or More Hours  
per Day – Is It Too Much? 
Characteristics of Very Old Persons 
(85+) According to Sleep Duration
Tatjana Škarić-Jurić
Institute for Anthropological Research, Zagreb
Introduction and Objectives. The extreme differ-
ences in daily sleep duration provoke questions on 
causality and “normal”/acceptable/recommended rang-
es. Specifically, it is often not clear whether and when 
should sleep duration be taken as a warning  signal, 
especially when a person’s well-being is under the in-
stitutional responsibility, as in retirement homes. This 
study aims at determining characteristics differing 
long (8.5+ hours), short (<6.5 hours), and mode-
rate/“normal” (6.5–8.0 hours) sleepers (in a 24h cycle) 
among the very old persons (85+ yrs.). Methods. The 
rich data collection on 327 very old persons living in 
retirement homes in Zagreb (HECUBA; CSF IP-01-
2018-2497) has been analyzed contrasting three simi-
larly sized groups: long-sleepers (95; 29.1%), short-
sleepers (102; 31.2%), and moderate-sleepers (130; 
39.8%). Results. Long-sleepers spend their leisure 
time more frequently with friends/neighbors (p=0.013) 
and less frequently walking (p=0.037). They more fre-
quently declare that somebody is with them during the 
night (p=0.020), that they have help in their everyday 
activities (p=0.028), and they are content with their 
present life (p=0.041). They less frequently think that 
loneliness is one of the main problems of the elderly 
(p=0.033). Long-sleepers less frequently report a 
chronic disease (p=0.033), and take medications for 
heart/blood pressure (p=0.037). Short-sleepers more 
frequently report that they were separated from their 
families because of their job (p=0.010), they are less 
frequently content with their past life (p=0.013), and 
now receive a lower pension (<4,000 HRK) (p=0.046). 
They more frequently declare that nobody is with 
them during the evening (p=0.022), and their main 
current problem is the feeling of uselessness (p=0.037). 
Short-sleepers more frequently report depression 
(p=0.029) and a chronic disease (p=0.047). Moderate-
sleepers more frequently have higher education 
(p=0.028), report that because of their education they 
changed their residence (p=0.046), and now have a 
higher pension (4,000–10,000 HRK) (p=0.036). They 
are also more frequently parents (p=0.046). Now they 
less frequently spend their leisure time with friends/
neighbors (p=0.027). Moderate-sleepers less frequent-
ly have heart problems (p=0.029) but more frequently 
have osteoporosis (p=0.015). conclusions. The study 
showed that in long-lived individuals the sleeping du-
ration is not related to sex and age/longevity or to the 
psychotropic drug usage, but is predominantly a re-
flection of the personality, quality of life, and life-long 
experience. The revealed pattern indicates that the 
very old persons sleeping less than 6.5 hours are the 
least content.
A3-P6
Cardiovascular and Metabolic 
Changes Related to Sleep and 
Ageing
Maja Valić, Renata Pecotić, Ivana Pavlinac Dodig,  
Linda Lušić Kalcina, Zoran Đogaš
Department for Neuroscience, University of Split School of Medicine, Split, Croatia
Sleep architecture and duration changes throughout 
the lifespan starting with dramatic changes during the 
first year of life, continuing to change through the 
childhood and finally becomes characterized by a re-
duction in sleep quality and quantity during ageing. 
Although total sleep time tends to remain constant, 
older people spend more time in the lighter stages of 
sleep, sleep latency might increase, REM sleep decline, 
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and sleep fragmentation occur. The prevalence of sleep 
disorders also tends to increase with age. As some 
sleep disturbances among the elderly could be consid-
ered as a physiological consequence of ageing, numer-
ous sleep disturbances can be attributed to illnesses 
and the medications used to treat them. Snoring is the 
primary cause of sleep disruption for approximately 
50% of older population. It is associated with over-
weight and often becomes worse with age. Loud snor-
ing is particularly serious as it can be a symptom of 
obstructive sleep apnea (OSA). Sleep is considered to 
be a modulator of metabolic homeostasis. The impact 
of sleep duration and sleep-disordered breathing in-
creases the risk for obesity, insulin resistance (IR), type 
2 diabetes (T2DM), the metabolic syndrome, and car-
diovascular disease risk and mortality. Prevalence of 
OSA is estimated to be 26% in adults 30–70 years old, 
and as high as 45% in obese adults. OSA is associated 
with ageing independently of obesity. The prevalence 
of OSA among older adults is substantially higher than 
in younger individuals. OSA is associated with an in-
creased risk for hypertension, possibly via blunting the 
normal nocturnal blood pressure dipping. The preva-
lence of OSA in adults with drug-resistant hyperten-
sion is as high as 83%. OSA is associated with an in-
creased risk of atherogenic dyslipidemia in adults 
showing higher total cholesterol and LDL levels, high-
er triglycerides levels, and lower HDL levels. OSA also 
increases the risk of cardiovascular and cerebrovascu-
lar diseases. The Sleep Heart Health study found that 
OSA is a significant, independent risk factor for 
chronic heart disease and heart failure in men aged 
40–70 years, and that OSA is increases the risk for 
ischemic stroke; even in men with very mild OSA. In 
summary, evidence shows that OSA increases the risk 
of cardiometabolic morbidities in the context of obe-
sity, hypertension, IR, and T2DM, atherosclerosis, 
CVD, stroke risk, and CVD-related mortality. Addi-
tionally, OSA is associated with ageing. Thus, untreat-
ed sleep apnea puts a person at risk for cardiovascular 




The Impact of Neuroscience 
Research in Europe for Healthy 
Ageing
Monica DiLuca
University of Milano, Italy; European Brain Council, Belgium
With a rapidly ageing population, dementia — par-
ticularly, Alzheimer’s disease (AD) — is a growing 
public health concern worldwide. In Europe, an esti-
mated 10.9 million people live with dementia, and this 
number is expected to increase to 18.7 million in 2050. 
AD is the underlying cause in 70% of people with de-
mentia. AD is a neurodegenerative disease that pro-
gresses in stages, beginning with a long silent phase 
before symptoms appear. The European Brain Council 
(EBC) is a network of key players in the “Brain Area”, 
with a membership encompassing scientific societies, 
patient organisations, professional societies and in-
dustry partners. Its main mission is to promote brain 
research with the ultimate goal of improving the lives 
of the estimated 179 million Europeans living with 
brain conditions, mental and neurological alike. With 
the aim to speak with one voice, EBC stands as the 
platform to foster cooperation between its member or-
ganisations and other stakeholders, consistently pro-
moting dialogue between scientists, industry and soci-
ety. Notably, EBC emphasizes the importance of rais-
ing awareness and encouraging education on the brain 
and the repercussions of neurological and mental 
health conditions on society as a whole; including dis-
eases like dementia and neurodegeneration, which are 
strongly influenced by an ageing population, where an 
increase in healthy ageing is desired. The promotion of 
healthy ageing will have massive implications not only 
on health care costs but also on the quality of life for 
the elderly. In fact, as demonstrated by EBC, in Europe 
it has been estimated that the total cost of brain dis-
eases on a yearly basis amounts to around 798 billion 
euro; for dementia only, the cost is 22.000 euro per pa-
tient, per year. These are facts and we need to face 
them: it is therefore obvious that research in the field 
of ageing and dementia is not only needed but it repre-
sents a societal obligation necessary to understanding 
the causes and developmental pathways of the disease, 
for its diagnosis, prevention and treatment. In this sce-
nario, and as part of the EBC value of treatment proj-
ect, the potential impact of a hypothetical Alzheimer’s 
medicine was assessed by researchers from Maastricht 
University, the Karolinksa Institute, the University 
Session A4: Neuroscience and Neurodegenrative Disorders and Ageing
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Medical Center Amsterdam and the London School of 
Economics. A treatment that would delay the rate of 
disease progression by 50% would have, as a conse-
quence, a smaller proportion of people progressing to 
advanced stages of the disease. This would result in an 
increase of quality adjusted life years (QALYs), a mea-
sure for both quality and the quantity of life lived, of 
1,75 per patient. Overall, a potential treatment is esti-
mated to reduce the total lifetime care costs by 12.406 
euro per person, per year. Considering the costs of de-
mentia for the European society and that these costs 
will increase considerably in the coming years due to 
the ageing of the European population, one way of 
curbing this increase and eventually decreasing the 
costs is via intensified research. It is therefore impor-
tant to focus our efforts on fundamental as well as in 
clinical neuroscience research. Only by improving the 
insight into the basic functioning of the brain and 
translating this knowledge to the disease state, under-
standing the causes of the disease process and paving 
the way for better targeted and improved treatment 
can the upwards spiral of the costs of brain disorders 
can be stopped. Furthermore, there is a constant need 
for strengthening the information flow and accelerat-
ing the exchange of experience on the on-going and 
future projects as well as maintaining continuous dia-
logue between all the stakeholder groups at the nation-
al and European level and initiatives to allow that ob-
jectives are aligned, and needs are met.
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Genes and Mechanisms 
Modulating Ageing and 
Neurodegeneration Derived  
From Studying Down Syndrome
Dean Nižetić
Barts & London School of Medicine, Queen Mary University of London, UK
Down Syndrome (DS) (caused by trisomy 21 (T21)) 
is an accelerated ageing condition on cellular and or-
ganism level. Paradoxically, people with DS have a 
much lower incidence and mortality from a range of 
solid tumours. They have an approximately 50–100 
fold higher overall incidence of leukaemias in child-
hood than normal children, including all types of 
acute myeloid leukaemia (AML) and B-cell acute lym-
phoblastic leukaemia (ALL). Children with DS are 
prone to suffer a relapse and have a higher risk of death 
from therapy-related side effects. Paradoxically 
though, individuals with DS have a substantially re-
duced incidence of second malignancies following ra-
diation therapy, even at a juvenile age, despite DS hae-
matopoietic cells in vivo showing a significantly in-
creased “passenger” mutation rate per year of age. We 
also detected that T21 causes a significantly increased 
number of DNA double strand breaks (γH2AX foci) in 
undifferentiated proliferating hiPSCs, post-mitotic 
neurons derived from hiPSCs, as well as in a trans-
chromosomic mouse model of DS. We also detected 
that IgG glycans in Down Syndrome individuals show 
extreme profiles that reflect accelerated aging. Experi-
ments aimed at identifying the chromosome 21 genes 
whose trisomic overdose is responsible for accelerated 
ageing and neurodegeneration using iPSC and other 
cellular models are on-going using iPSCs from partial 
trisomy 21 cases, as well as CRISPR/Cas9-edited triso-
my-correction for specific genes. Using isogenic T21-
iPSC-derived cerebral organoids, we also identified a 
novel mechanism that delays the onset of Alzheimer’s 
disease, despite the triplication of the myloid precur-
sor protein (APP) gene in T21.
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A4-O2
The ALZENTIA System:  
A Sensitive Non-invasive  
Hidden-Goal Test for Early 
Cognitive Impairment Screening
Goran Šimić
Department of Neuroscience, Croatian Institute for Brain Research, School of Medicine, 
University of Zagreb, Croatia
There is a need to identify reliable predictors of mild 
cognitive impairment (MCI) and dementia due to Al-
zheimer’s disease (AD) in normal elderly people to en-
able timely intervention. The Mini‐Mental State Ex-
amination (MMSE) is the best‐known and the most 
often used short screening tool for providing an over-
all measure of cognitive impairment in clinical, re-
search, and community settings. However, MMSE is 
not actually a mental status examination designed to 
detect dementia as it was originally developed to dif-
ferentiate organic from functional psychiatric patients. 
The MMSE has low sensitivity in detecting dementia 
as well as poor specificity, and low negative (NPV), 
and positive predictive values (PPV), especially in ear-
ly-stage AD. A recent systematic review also did not 
find evidence supporting a substantial role of MMSE 
as a stand‐alone single‐administration test in the iden-
tification of MCI patients who could develop dementia 
(Cochrane Database Syst Rev. 2015: CD010783). We 
have developed a new system (ALZENTIA) that helps 
detect early MCI, mainly caused by AD. This system 
consists of original software and hardware, and stems 
from the original efforts by the late Jan Bures and his 
colleagues to develop a hidden-goal task (HGT) test in 
which the human subject has to find a target that is not 
visible; instead, the navigation must be based on a pre-
viously memorized target position, in relation to the 
starting position and/or other navigational landmarks 
(orientation cues). The average duration of the test is 
approximately 25 min. per subject. Our preliminary 
results obtained on 91 healthy controls (HC) and 33 
MCI patients have been recently published (J. Neuro-
sci. Methods, 2020; 332: 108547). Receiver operating 
characteristic (ROC) analysis revealed that two mea-
surements (variables) reached 85% or higher sensitiv-
ity and specificity: combined allocentric-egocentric 
average error of all 8 attempts, and egocentric average 
error of the first 4 attempts. The high NPVs (over 90% 
in almost all subtests and at all prevalences) suggested 
high discriminative capacity and diagnostic potential 
for the ALZENTIA system as a tool to detect subjects 
in healthy population who will progress to MCI. Con-
sidering the low sensitivity of the MMSE and Montreal 
Cognitive Assessment (MoCA) tests currently used for 
this purpose, we believe that ALZENTIA can signifi-
cantly improve early identification of MCI patients 
who will progress to AD. Funded by the Croatian Sci-
ence Foundation and HAMAG-BICRO.
A4-O3
Genomic Diagnostics in Patients 
with Neurodegenerative Diseases
Fran Borovečki
Department of Neurology, University Hospital Centre Zagreb, School of Medicine, 
University of Zagreb, Croatia
Neurodegenerative diseases are characterized by 
progressive nervous system dysfunction caused by the 
death of neurons in the brain and spinal cord. Given 
the prevalence, clinical hallmarks and associated costs 
of treatment, neurodegenerative diseases represent a 
significant and ever increasing public health problem. 
Despite extensive clinical research and dynamic devel-
opments in the field of neurology, especially regarding 
the development of new disease-modifying drugs and 
therapeutic procedures, there is still no effective medi-
cine capable of stopping or even slowing neurodegen-
erative processes. A growing body of research points 
to the clear role of genetic mechanisms in the develop-
ment of neurodegenerative diseases such as Alzheim-
er’s and Parkinson’s disease or Amyotrophic lateral 
sclerosis. Insight into the human genome structure 
provides key information on possible hereditary dis-
eases and genetic rearrangements which can cause 
common and rare variants of the genotype. Although 
numerous genes are responsible for the appearance of 
monogenic forms of neurodegenerative diseases, in 
most cases, inheritance is genetically complex and oc-
curs through the interaction of multiple genes and the 
environment. Genomic approaches, such as gene chips 
or next generation sequencing, provide a better insight 
into the genetic risk factors that are responsible for 
neurodegenerative diseases. Next generation sequenc-
ing approaches such as whole-genome, exome and 
panel sequencing have greatly enhanced our ability to 
detect genetic causes of neurodegenerative diseases. 
Novel genomic approaches will enable in the future 
not only the detection of new genetic risk variants, but 
will also contribute to increased treatment efficiency 
and reduce the frequency of adverse events to existing 
and future therapies.
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A4-P1
Challenges in Headache 
Treatment in Elderly
Marija Ana Bosnar Puretić
Department of Neurology, University Hospital Centre Sestre Milosrdnice,  
School of Medicine, University of Zagreb, Croatia
Headaches occur less frequently in the elderly than 
in the younger and middle-aged population, but are 
nevertheless a challenge for diagnosis and treatment. 
Any headache that first occurs in the elderly must 
arouse suspicion of a secondary headache and require 
diagnostic workup, including a brain imaging. In addi-
tion to primary and secondary brain tumors and intra-
cranial haemorrhage, headache in the elderly may also 
be a consequence of systemic diseases such as arterial 
hypertension, polymyalgia rheumatica and giant cell 
arteritis, which also require treatment as soon as pos-
sible. Particular problems in older age are the primary 
headaches that continue since patient’s young or mid-
dle-age, persistent in frequency and intensity. The 
treatment of such patients is a problem because of the 
comorbidities that limit pharmacotherapy, the limita-
tions on the use of specific migraine drugs – triptans, 
polypragmasy and psychiatric comorbidities. The 
complexity of treating elderly patients with headache 
are best described by following case reports from ev-
eryday practice: 73 year-old female patient with tri-
geminal neuralgia, 77 year-old female patient with 
temporal arteritis, 90 year-old female patient with fre-
quent tension-type headache, and 68 year-old male 
patient with chronic migraine. If left untreated, head-
aches significantly reduce the quality of life of elderly 
patients already burdened with other diseases and 
conditions and can lead to the occurrence of medica-
tion overuse headache.
A4-P2
Hallmarks of Corticogenesis  
After Ischemic Stroke in Mice
Dunja Gorup, Sanja Srakočić, Srećko Gajović
Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Croatia
Introduction and objectives. Stroke represents the 
most common acute neurological condition leading to 
permanent disability, and as such a significant burden 
of disease in a modern aging society. Animal models 
of ischemic stroke mirror the postischemic changes at 
the molecular and cellular level, enabling the study of 
recovery mechanisms, that are presumably based on 
revoking the process of corticogenesis. The goal of this 
study was to identify the role of prominent markers of 
corticogenesis, SatB2 and Ctip2, in postischemic re-
covery. Methods. Transient middle cerebral artery oc-
clusion (tMCAo) was performed on male adult C57Bl6 
mice (n = 5) and the lesion was followed up using 7T 
BioSpec MRI system, as well as observing neurological 
deficit (NS) in the analysis of behaviour (Day 3, 7). 
Control group underwent the sham surgery. From Day 
3 to 7 both groups received 5 dosages of 5-bromo-2’-
deoxyuridine (BrdU) in order to mark the newly pro-
liferating cells. On the day 7 mice were anaesthetized, 
perfused by saline and 4% paraformaldehyde (PFA) to 
preserve the brain anatomy for immunofluorescence 
(IF) using antibodies specific for SatB2, Ctip2, NeuN, 
cCASP3, GFAP and BrdU. Slides were imaged using 
the confocal microscope (Olympus, CIBR) and posi-
tive cells were counted for each marker in the ipsilat-
eral (IL) and contralateral (CL) cortex, hippocampus 
and striatum. Results were correlated to the lesion size 
determined by the MRI and cresyl-violet slides, and to 
the neurological score. Results. The lesion was the 
largest on the Day 3 after tMCAo, and this was in pos-
itive correlation with the ND. IF signal of SatB2 and 
Ctip2 was significantly different between the IL and 
CL hemispheres of the tMCAo mice, and in compari-
son to the sham operated group. Also, the amount of 
cells co-expressing both markers increased after 
tMCAo, as well as the number of BrdU positive cells. 
GFAP has shown an astrocytic reaction, while the total 
number of neurons (NeuN) was impaired in IL hemi-
sphere after tMCAO. conclusions. Subacute stage of 
ischemic stroke in mice includes increased prolifera-
tion of cells, as well as the changes in the neuronal cor-
tical profiling (SatB2, Ctip2) that resemble immature 
patters during corticogenesis. Modulation of those 
events could not only prevent the postischemic epilep-
togenic conversion, but also enhance the speed and 
quality of rehabilitation in affected patients.
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A4-P3
Effects of Age on Retinal 
Macrophage Responses to Acute 
Elevation of Intraocular Pressure
Jelena M. Kezić1,2,3, Vicki Chrysostomou2,4, Paul G. McMenamin3,  
Jonathan G. Crowston2,4
1  Department of Histology and Embryology, School of Medicine, University of Zagreb, 
Zagreb,Croatia
2  Centre for Eye Research Australia, University of Melbourne,  
Royal Victorian Eye and Ear Hospital, Melbourne, Australia
3  Department of Anatomy and Developmental Biology, Monash University,  
Melbourne, Australia
4  Centre for Vision Research, Duke-NUS Medical School and Singapore Eye Research 
Institute, Singapore
Introduction and objectives. There is accumulating 
evidence that aging shifts the central nervous system 
milieu towards a proinflammatory state, with in-
creased reactivity of microglia in the aging eye and 
brain having been implicated in the development of 
age-related neurodegenerative conditions. Indeed, al-
terations to microglial morphology and function have 
been recognized as a part of normal aging. Here, we 
sought to assess the effects of age on the retinal mi-
croglial and macrophage response to acute intraocu- 
lar pressure (IOP) elevation and further, determine 
whether the age of bone marrow would alter the mac-
rophage response to injury in bone marrow chimeric 
mice. Methods. For the first part of this study, 
C57BL/6J mice of 3 and 12 months of age underwent 
IOP elevation. Briefly, the anterior chamber was can-
nulated and intraocular pressure elevated to 50 mmHg 
for 30 minutes. Control eyes were cannulated and 
pressure was maintained at physiological IOP (12 mm 
Hg). In the second part of this study, bone marrow 
from young (8 week old) or middle-aged (12 month 
old) mice was used to reconstitute the bone marrow of 
whole-body irradiated 12 month old mice. Bone mar-
row chimeric mice underwent cannulation and IOP 
elevation 8 weeks after bone marrow transplantation. 
For both studies, eyes were collected for analysis 1 
week after IOP elevation. Immunofluorescence stain-
ing was performed on retinal wholemounts to assess 
changes to the density of retinal macrophages, microg-
lial process length and activation of glial cells. Results.
Retinal macrophage reactivity and microglial mor-
phological changes were enhanced in older mice when 
compared to younger mice in response to injury. 
When IOP elevation was performed after whole-body 
irradiation and bone marrow rescue, we noted a re-
duction in subretinal macrophage accumulation and 
attenuation of glial reactivity compared to non-irradi-
ated mice that had also undergone IOP elevation. This 
effect was evident in both groups of chimeric mice that 
had received either young or middle-aged bone mar-
row. conclusions. Our data suggest irradiation itself 
may alter the macrophage and glial response to retinal 
injury rather than the age of bone marrow.
A4-P4
Cognitive Training:  
New Therapeutic Approach  
to the Patients with Mild 
Cognitive Impairment
Nataša Klepac
Department of Neurology, University Hospital Centre Zagreb, School of Medicine, 
University of Zagreb, Croatia
Cognitive training (CT) has attained attention as a 
non-pharmacological approach to maintain cognition 
in older adults. CT involves guided drill-and-practice 
on standardized tasks designed to load on specific cog-
nitive processes, typically without explicit teaching of 
memory or problem-solving strategies. CT can target 
multiple domains and usually adapts task difficulty to 
individual performance. Recent randomized control 
trials and meta-analyses of experimental studies indi-
cate positive effects of CT on the cognitive function of 
healthy older adults but also patients that demonstrate 
impaired cognitive functions due to several reasons. 
Furthermore, a large-scale randomized control trial 
with older adults, independent at entry, indicated that 
CT delayed their cognitive and functional decline over 
a five-year follow-up. This supports CT as a potentially 
efficient method to postpone cognitive decline in per-
sons with mild cognitive impairment (MCI) and CT as 
therapeutic option able to prevent or delay cognitive 
or functional decline. Training in elderly with MCI 
had greater effect in the younger old and more cogni-
tively preserved individuals. In MCI, CT is efficacious 
on global cognition, memory, working memory, and 
attention and helps improve psychosocial functioning, 
including depressive symptoms. Effect of CT was cor-
roborated by a moderate effect size on common clini-
cal measures of global cognition (mainly the Mini-
Mental State Examination). Moderate effect sizes on 
memory is encouraging, as amnestic MCI profiles are 
at higher risk for dementia conversion. Participants in 
CT groups improved significantly over the interven-
tion period but there are still insufficient data to deter-
mine whether training gains can be maintained over 
the long-term without further training. Cognitive in-
terventions can contribute toward promoting health 
and independence among patients with MCI. Further 
investigations in large samples with long follow up pe-
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riod are now warranted to verify the role of cognitive 
interventions as reliable tool to prevent cognitive func-
tions and wellbeing.
A4-P5
Role of Vibrational Spectroscopy in 
the Early Detection of Glaucoma
Tena Križ1, Mia Zorić Geber1, Tin Šklebar3 ,Lorena Karla Rudež3,  
Katia Novak Lauš1,  Marko Škrabić2 , Ozren Gamulin3, Zoran Vatavuk1
1  Department of Ophthalmology, University Hospital Centre Sestre Milosrdnice,  
Zagreb, Croatia
2  Department of Physics and Biophysics, School of Medicine, University of Zagreb, 
Croatia
3  School of Medicine, University of Zagreb, Croatia
Introduction and objectives. Glaucoma is a disease 
of the optic nerve that causes retinal ganglion cell 
(RGC) decay and retinal nerve fiber layer (RNFL) 
thinning, resulting in the visual field damage. It is one 
of the major causes of irreversible blindness in the 
world and is therefore a major public health problem 
since. Also, it is estimated that 80 million people will 
suffer from glaucoma by 2020. The most common type 
of glaucoma is primary open-angle glaucoma (POAG), 
and, despite numerous studies, the exact pathomecha-
nism of its occurrence has not yet been determined. 
Numerous risk factors for the onset and progression of 
glaucoma have been identified, the most important 
being the height of intraocular pressure (IOP), the de-
gree of damage at the time of diagnosis and the life 
expectancy of the patient. Currently, the only treat-
ment option to slow the progression of the disease is to 
lower IOP. The goal is to detect glaucoma as early as 
possible to ensure the best possible quality of life and 
prevent blindness. Since there are currently no glauco-
ma-specific biomarkers yet identified and no glauco-
ma screening method available, we decided to analyze 
molecular structure of aqueous humor using FTIR 
spectroscopy which offers a unique opportunity to in-
vestigate the composition of unknown substances on a 
molecular basis. Methods. The study included 80 age 
matched subjects from the Reference Center for Glau-
coma, UHC “Sestre milosrdnice”, divided into two 
groups 1) 40 glaucoma patients and 2) a control group 
comprising 40 patients with cataracts. For the purpose 
of molecular analysis, all aqueous humor samples were 
collected at the start of the glaucoma or cataract sur-
gery. FTIR spectra of the samples dried on transparent 
silicon windows were obtained in a transmission 
mode, followed by principal component analysis 
(PCA) modeling of the recorded spectra. Results. 
FTIR spectra with vibrational modes specific to glau-
coma and cataract were examined. In the chemomet-
ric analysis of the spectroscopic data, all 40 (100%) of 
the cataract eyes were correctly diagnosed as the cata-
ract group and all 40 (100%) glaucoma eyes were diag-
nosed as the glaucoma group, demonstrating a distinct 
correlation between studied eye diseases and their 
FTIR spectra. conclusions. FTIR spectroscopy com-
bined with the chemometrics has proven to be a prom-
ising method for molecular analysis of the aqueous 
humor as the differentiation between eyes with cata-
ract and glaucoma has been achieved. Separation of 
the two groups of FTIR spectra in the created PCA sta-
tistical model also indicates that this method may have 
a promising role in the discovery of glaucoma bio-
markers.
A4-P6
BDNF, IL-6, PPARγ Gene  
and BDNF Protein 
Polymorphisms in Patients  
with Glaucoma
Tena Križ1, Jadranka Sertić2,3, Ana Merkler2, Ana Kozmar2,  
Mia Zorić Geber1, Katia Novak Lauš1, Zoran Vatavuk1
1  Department of Ophthalmology, University Hospital Centre Sestre Milosrdnice,  
Zagreb, Croatia
2  Department of Laboratory Diagnostics, University Hospital Center Zagreb, Croatia
3  Department of Medical Chemistry, Biochemistry and Clinical Chemistry,  
School of Medicine, University of Zagreb, Croatia
Introduction and objectives. Glaucoma is a slowly 
progressive, chronic optic neuropathy that is charac-
terized by retinal ganglion cell (RGC) death with sub-
sequent loss of optic nerve axons and decrements in 
visual function. It is one of the major causes of irre-
versible blindness in the world and is a major public 
health problem. It is estimated that 80 million people 
will suffer from glaucoma by 2020. Several types of 
glaucoma are known, and the most frequent is prima-
ry open-angle glaucoma (POAG). Despite numerous 
studies, the exact pathomechanism of its occurrence 
has not yet been determined. Current treatment for 
glaucoma is directed toward lowering the IOP, but this 
approach only limits disease progression. The goal is 
to detect glaucoma as early as possible to ensure the 
best possible quality of life and prevent blindness. The 
molecular events responsible for glaucoma are cur-
rently poorly understood, complicating the design of 
therapies based on the underlying disease mecha-
nisms. Since glaucoma is accompanied by profound 
biochemical changes, proteomic profiling or specific 
biomarker detection in the aqueous humor may be a 
way to follow glaucoma progression and potentially to 
monitor treatment efficacy. The aim of this study is to 
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analyze the concentration of BDNF in aqueous humor 
and serum and to identify polymorphisms of the 
BDNF, IL-6 and PPARγ genes. Methods. The study in-
cluded 145 age matched subjects from the Reference 
Center for Glaucoma, UHC “Sestre milosrdnice”, di-
vided into two groups 1) 83 glaucoma patients and 2) 
a control group comprising 62 patients with cataracts. 
For the purpose of molecular analysis, all aqueous 
humor samples were collected at the start of glaucoma 
or cataract surgery. BDNF concentration was mea-
sured in aqueous humor and serum by ELISA method 
and BDNF polymorphism (Val66Met, VM), IL-6 
(-174, GC) and PPARγ (Pro12Ala, CG) by PCR-RFLP. 
Results. BDNF concentration in serum and aqueous 
humor: glaucoma /cataract 13.0/13.9 ng/mL and 
4.5/3.0 pg/mL. Polymorphism gene distribution (%): 
BDNF VV 61.4/58.1, VM 36.1/35.5, MM 2.4/6.5; IL-6 
GG 38.9/41.9, GC 45.8/41.9, CC 13.3/16.1; PPARγ CC 
75.9/74.2, CG 21.7/24.2, GG 2.4/1.6. conclusions. 
Preliminary polymorphism results indicate possible 
polygenic markers of BDNF MM, IL-6 CC, and PPARγ 
GG and differences in aqueous humor BDNF con-
centration between examinee with glaucoma and cata-
ract. Given the difference in the concentration of 
BDNF in aqueous humor between two groups, the 
 potential for new treatment modalities opens. More 
research on a larger number of samples is needed to 
better understand the role of gene and polygenic 
markers in glaucoma.
A4-P7
Lend a Hand Project
Sonja Tošić Grlač, Valentina Biševac
Međimurje County
The project „Lend a hand“ solves the issue of social 
exclusion of people with Alzheimer’s dementia and 
other forms of dementia in the Međimurje County, 
Krapina-Zagorje County, Požega-Slavonia County, Osi-
jek-Baranja County and Koprivnica-Križevci County 
by improving the quality of life of the patients and 
their families. The purpose of the project is to include 
30 Alheimer affected persons into the community, 
therefore preventing their premature institutionaliza-
tion. This will enable family members to reconcile be-
tween family and business life. This will be achieved 
during the 18 months the expert team will work daily 
with the patients. The general public will become more 
aware of Alzheimer’s dementia and other forms of de-
mentia through the Alzheimer cafe opening in 5 coun-
ties. Dementia, as a progressive and incurable illness, 
quickly leads to loss of independence and thus directly 
affects the families of patients, leading to physical, psy-
chological, emotional and financial exhaustion. Family 
caregivers sometimes find it difficult to find a balance 
between work and family life, so they need help and 
support of the community which often doesn’t under-
stand the needs of patients and their families. A big 
issue is the late diagnosis of dementia, since the early 
symptoms of the disease are difficult to recognize. The 
project contributes to preventing the early institution-
alization of patients, enables a better work-life balance 
for family members caring for patients, and increases 
the number of professionals working with patients. 
The Call Center will also support the whole commu-
nity. The target groups of the project are people with 
Alzheimer’s and other dementias, their families, the 
professionals who work with them as well as the gen-
eral public.
50
LIJEČ VJESN 2020; godište 142; supplement 1; 29–63 Main Topic A Ageing of Biological Systems
Invited lecture
A5-I
Good Clinical Practices for the 
Improvement of the Age-Related 
Diseases
Alpana Mair
Scottish Government, Scotland, UK
The rise in the prevalence of multimorbidity (the co-
occurrence of two or more chronic medical conditions 
in an individual person) in ageing societies is one of 
the greatest challenges now faced by health services 
internationally. Despite this, most medical research, 
guidelines, and contractual agreements (such as pay-
for-performance initiatives) are focused on the man-
agement of single disease states. In these patients, indi-
vidually treating each condition inevitably leads to the 
use of multiple medications (polypharmacy), the risks 
and benefits of which are largely unproven and often 
unpredictable.
It is important to note that polypharmacy is not in-
appropriate per se, and it is often beneficial. For ex-
ample, effective secondary prevention of myocardial 
infarction requires the use of at least four different 
classes of drugs (antiplatelets, statins, angiotensin-
converting enzyme inhibitors, and beta-blockers How-
ever, polypharmacy becomes inappropriate when the 
risks of multiple medications begin to outweigh their 
potential benefits for an individual patient. The risk of 
harm is generally higher in older people with multi-
morbidity than in younger patients due to their re-
duced ability to clear drugs (e.g., due to renal and/or 
hepatic impairment) and increased vulnerability to 
drugs’ adverse effects (due to general frailty and drug–
drug and drug–disease interactions) and medication 
burden . However, the increased risk of harm is not 
always offset by increased benefits, and for many pre-
ventive medicines, such benefits may never be realized 
due to a shortened life expectancy.
There is mounting evidence that polypharmacy is a 
public health threat and a major source of unnecessary 
harm, greater use of health services, hospitalization, 
reduced quality of life, and substantial financial cost to 
health-care systems. In 2012, the US Institute for 
Healthcare Informatics estimated that inappropriate 
polypharmacy contributes to 4% of the avoidable costs 
of health care, equating to an expenditure of $18 bil-
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lion worldwide, and one recommendation was to sup-
port pharmacist collaboration with physicians for 
medication reviews. Up to 11% of unplanned hospital 
admissions in the UK are attributable to mostly avoid-
able harm from medicines, and of these, over 70% are 
in elderly patients on multiple medicines. There are, 
therefore, significant opportunities to reduce this bur-
den by timely and effective interventions. If this was 
extrapolated across the EU, this would result in 8.6M 
admissions . Similarly, it has been found that medicine 
related visits accounted for 12.5% of attendances, the 
main causes being adverse drug reactions (ADR) and 
non-adherence to medicines (33% and 19% respec-
tively). The EU SIMPATHY project, evaluated all the 
guidance documents that were available across the EU. 
The literature review identified that there are guidance 
documents available relating to the management of 
polypharmacy in only 3 of the 28 EU countries only 
the guidance documents from Scotland, Netherlands 
and Germany score the maximum on the AGREE II-
GRS criteria for quality. The third edition of Polyphar-
macy Guidance, Realistic Prescribing, published in 
2018, aims to provide guid ance on preventing inap-
propriate polypharmacy at every stage of the patient 
journey. It contains a clear structure for both the ini-
tiation of new treatments and the review of existing 
treatments, and has been updated to place a greater 
emphasis on “what mat ters to the patient?” The 7 steps 
were informed by existing literature and initially 
agreed upon and subsequently refined (based on feed-
back from practicing clinicians and patients) by a 
guideline development group comprising a mix of 
pharmacists and primary (general practitioners) and 
secondary care physicians with backgrounds in clini-
cal practice and academia.
Agreeing specific objectives with the patient in 
terms of both therapeu tic objectives and current life 
priorities (step 1) sets the context within which all fur-
ther decisions are made, namely on which medicines 
are essential (step 2) or unnecessary (step 3), whether 
therapeutic objectives that matter to the patient are 
achieved (step 4), which medicines are too risky or 
cause unacceptable adverse effects (step 5), which 
medicines are not cost effective (step 6), and whether 
the patient is willing and able to manage their medi-
cines in a way that avoids harm and maximises benefit 
(step 7).
While guideline development is a necessary first 
step, improving patient outcomes relies on their effec-
tive implementation. The challenge of safely using 
multiple medicines for patients with multiple morbid-
ities is beginning to gain international attention. In 
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April 2017, at the European launch of the SIMPATHY 
publication Polypharmacy Management by 2030: A Pa-
tient Safety Challenge (15), the Scottish Cabinet Secre-
tary for Health called on the other 27 EU counties to 
take action on addressing polypharmacy, and this was 
also supported by WHO. This work has identified six 
key recommendations to implement programs to im-
prove medication safety, of which polypharmacy is an 
essential element: (a) Use a systems approach that has 
multidisciplinary clinical and policy leadership; (b) 
nurture a culture that encourages and prioritizes the 
safety and quality of prescribing; (c) ensure that pa-
tients are integral to the decisions made about their 
medicines and are empowered and supported to do so; 
(d) use data to drive change and measure outcomes; 
(e) adopt an evidence-based approach with a bias to-
ward action; and (f) utilize, develop, and share tools to 
support implementation. The WHO Third Global Pa-
tient Safety Challenge (12), Medication Without Harm, 
has included the appropriate management of poly-
pharmacy as a key flagship area to address across 
health care systems.
R e f e R e n c e s
1. Mair A, Wilson M, Dreischulte T. Addressing the Challenge of 
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ogy 2020; 60:1,661–681.
2. Mair A. Medication safety in polypharmacy, Third Global Pa-
tient Safety Challenge., World Health Organ, Geneva: 2019.
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Early Intervention Optimizes 
Long-Term Treatment Results  
in Patients with Inflammatory 
Rheumatic Diseases
Branimir Anić, Ivan Padjen, Boris Karanović, Miroslav Mayer
Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, 
University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Croatia
Rheumatic diseases are a prevalent group of entities 
with a significant impact on quality of life and morbid-
ity in the population. Progress in rheumatology over 
the last 20 years has led to a significant increase in 
overall life and work prognosis. Rheumatoid arthritis 
(RA) decreases life expectancy by 10 years. Inade-
quately treated patients with active RA develop irre-
versible functional impairment in over 50%. Introduc-
tion of new drugs – biological and targeted synthetic 
agents – has changed treatment outcomes tremen-
dously. In addition to the evolvement of therapy, new 
diagnostic algorhythms have enabled early diagnosis. 
Adequate timing of contemporary treatment that is 
available in Croatia has led to prevention of disability, 
decline in sick leave, prolongation of time actively 
spent at work, as well as increased survival. Over 800 
patients have been treated with targeted therapies at 
our institution – 650 are currently under treatment. 
Continuous and focused education of family physi-
cians over the past 10 years enabled us to optimize 
screening of incident patients. The latter serves as a 
prerequisite for better treatment outcomes. Systemic 
lupus erythematosus (SLE) is a typical systemic in-
flammatory rheumatic disease. Five-year survival in 
the 1950s was 50%, in contrast to 95% at the beginning 
of this century. Data from the literature suggested a bi-
modal mortality pattern. Results of a study performed 
in Croatia demonstrated a 5-year survival of 90%. 
However, the study did not confirm a bimodal pattern: 
this may be explained by a decline in early mortality 
owing to early diagnosis and therapy, as well as by a 
lack of complications of aggressive therapy. This study 
demonstrated problems in the collection of public 
health data for patients with SLE. Insufficiency of the 
current criteria for SLE has resulted in a project within 
an international working group and, subsequently, 
proposal and publication of new criteria for the diag-
nosis of SLE (our Division was included as the Referral 
Center for SLE of the Croatian Ministry of Health). 
Progress has been noted in the diagnosis and treat-
ment of common rheumatic diseases of the elderly 
such as polymyalgia rheumatica and giant cell arteri-
tis. Our experience in the use of contemporary thera-
peutics showed good results and better treatment tol-
erance. Finally, further steps have been noted in the 
treatment of osteoarthritis, commonly perceived as 
the most important rheumatic disease in the elderly. 
Improvement of surgical techniques and higher quali-
ty endoprostheses have increased treatment outcomes. 
Steps forward in the area of osteoarthritis pharmaco-
therapy have also been observed.
A5-O2
Pharmacogenomics  
– a Promising Tool for Elderly 
Patients on Polytherapy
Nada Božina1, Nikica Mirošević Skvrce2, Lana Ganoci3,  
Iva Klarica Domjanović2, Livija Šimičević3, Tamara Božina4,  
Vladimir Trkulja5, Viola Šarinić-Macolić6
1  Department of Pharmacology, University Hospital Centre Zagreb, School of Medicine, 
University of Zagreb, Croatia
2  Croatian Agency for Medicinal Products and Medical Devices, Zagreb, Croatia,
3  Department of Laboratory Diagnostics, Division of Pharmacogenomics  
and Therapy Individualization, University Hospital Centre Zagreb, School of Medicine, 
University of Zagreb, Croatia
4  Department of Medical Chemistry, Biochemistry and Clinical Chemistry,  
School of Medicine, University of Zagreb, Croatia
5  Department of Pharmacology, School of Medicine, University of Zagreb, Croatia
6  European Medicines Agency (EMA), Amsterdam, The Netherlands
Introduction and objectives. Polypharmacy is prev-
alent in elderly patients and is associated with drug-
drug interactions, adverse drug reactions (ADRs), 
more frequent hospital admissions and higher health-
care costs. A pharmacogenomic approach enables per-
sonalized medication regimens based on individual 
genetic variations predominantly of ADME genes, in-
volved in the pharmacokinetics of medicinal products. 
The majority of current pharmacogenomic decision 
support tools provide assessment only of single drug-
gene interactions without taking into account complex 
drug-drug and drug-drug-gene interactions which are 
prevalent in polypharmacy and can result in ADRs or 
insufficient drug efficacy. Genotyping of metabolic en-
zymes of phase I (CYPs, DPD), phase II (TPMT, UGTs, 
NAT2), ABC, SLC transporters, and drug targets, rep-
resents a valuable tool for analysing the causal rela-
tionship between drug intake and dose related ADRs. 
The availability of genomic testing has grown, but its 
clinical application is still insufficient. The objective 
was to develop comprehensive pharmacogenomic de-
cision support for medication risk assessment in el-
derly polymedicated patients. Methods. To study the 
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possible genetic associations with ADRs, School of 
Medicine University of Zagreb, University Hospital 
Centre Zagreb, and Croatian Agency for Medicinal 
Products & Medical Devices (HALMED) have piloted 
a project to collect DNA and phenotype data of ADR 
cases using international standardized phenotypic cri-
teria. Patients with ADRs (N=860) and controls were 
genotyped for pharmacogenes. Univariate and multi-
variate prediction of ADRs were carried by means of 
binary logistic regression in order to identify novel as-
sociations or validate findings in cohorts of patients 
with well-defined phenotypes. Results. We developed 
a comprehensive knowledge repository of actionable 
pharmacogenes. HALMED developed a method for 
informing physicians or pharmacists and their pa-
tients about a possible pharmacogenetic involvement 
in the ADR pathogenesis. An anonymized copy of the 
test results has been used for the interpretation of pos-
sible signals. Several publications from this project 
have been published, depending on the medication in 
question (warfarin, statins, clopidogrel, methotrexate, 
AEDs, psychotropic drugs). conclusion. Pharmacoge-
nomic knowledge repository is an excellent starting 
point for pharmacogenomic testing implementation 
in clinical practice and pharmacogenetic counselling 
after a reported ADR. By using a pharmacogenomics 
approach, individualized strategies in medication can 
improve drug safety and efficacy in the elderly patient 
population.
A5-O3
International Networking  
and Clinical Practice  
in Neurodegenerative Diseases
Ervina Bilić, Barbara Sitaš, Hrvoje Bilić, Mirea Hančević, Fran Borovečki
Department of Neurology, University Hospital Centre Zagreb, School of Medicine, 
University of Zagreb, Croatia
Aging is a well-known risk factor for neurodegen-
erative disease. As world population is continuously 
aging, both incidence and prevalence of neurodegen-
erative diseases are rising.
The term neurodegeneration means that there is an 
irreversible loss of neurons. Available treatments can 
only modify and slow down the natural course of the 
disease, but not stop disease progression. Therefore, it 
is not surprising that the field of research and interest 
in these diseases is continuously growing. Amyo-
trophic lateral sclerosis (ALS) is a neurodegenerative 
disease characterised by progressive loss of motor neu-
rons leading to death in 3–5 years from symptom 
onset. Since there is still no cure, treatment is based on 
a multidisciplinary approach in palliative care to im-
prove the quality of life. To improve care and make ex-
pensive clinical research more available to our patients, 
Centre for Neuromuscular diseases and Clinical Elec-
tromyoneurography, Clinical hospital centre Zagreb 
became a member of ENCALS (European network to 
cure ALS) in 2017.
After joining the network, our Centre continued to 
provide up-to-date medical care, treatment and sup-
port for patients with ALS as well as actively seeking 
ways to contribute to the pool of knowledge about 
motor neuron disease. This is reflected in activities un-
dertaken over the last two years – clinically based reg-
istry of ALS patients was created as well as blood and 
CSF bank. Registry provided up to date epidemiologi-
cal data about Centre’s patient population. We includ-
ed new members into our multidisciplinary team with 
genomics and sleep disorders specialists. Following 
this team expansion first genetic testing results for 
Centre’s patients with familial ALS are available. All of 
this enabled us to join TRICALS research initiative to 
find cure for ALS. Centre has also started validation 
and standardisation of the Croatian ECAS (Edinburgh 
Cognitive and Behavioural ALS screen) in collabora-
tion with Prof. Abrahams’ team from University of Ed-
inburgh. Following this, same is intended with DAS 
(Dimensional Apathy Scale). Currently our Centre is 
exploring the quality of life of patients with ALS (first 
results pending). Considering all of the above it ap-
pears there has been a change in Centre’s activity with 
increased productivity and improved structure, and 
change in team’s attitude from mechanistic to optimis-
tic which is sometimes even more difficult to achieve.
In this report we want to illustrate the practical im-
portance of clinical and scientific network and its pos-
itive impact in everyday quality of clinical work in the 
demanding field of neurodegenerative diseases, espe-
cially ALS.
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Common Clinical Challenges 
When Prescribing Dermatologic 
Therapy in Geriatric Patients
Anamaria Balić, Branka Marinović, Romana Čeović, Zrinka Bukvić Mokos
Department of Dermatology and Venerology, University Hospital Center Zagreb,  
School of Medicine, University of Zagreb, Croatia
One hundred years ago, only 2% of the U.S. popula-
tion was over 65 years old. By 1980, this percentage 
was 11%, and by the year 2030, it will be 20%. With 
this tremendous increase in the proportion of elderly 
in the global population, geriatric medicine has be-
come of great interest and importance. Data shows 
that around 40% of Americans between the ages of 65 
and 74 years have had a skin disease significant enough 
to warrant treatment by a physician. Given the high 
incidence of significant dermatologic disorders in the 
elderly, it is clear that all health providers need to fa-
miliarize themselves with the diagnosis, prevention, 
and treatment of skin diseases seen in this population. 
The mainstay of therapeutic approach in the elderly 
should be proper skincare and treatment due to the 
preventable nature of most of the age-related skin dis-
eases or treatable nature of another skin disease with 
their age-related specificities. Particular attention 
needs to be directed towards geriatric dermato-phar-
macology as an ageing population has brought many 
therapeutic challenges that we need to recognize and 
overcome. Safely prescribing in the field of geriatric 
dermatology is a complicated task since there is an in-
creased risk of drug interactions that may be caused by 
various factors including the prescribing factor, pa-
tient-related factors or difficulties within the health-
care system such as poor or insufficient communica-
tion between the patients and medical professionals. 
Dermatologists and other specialists should be aware 
that prescribing medicines to their mature patients is a 
dynamic process that involves many patient-doctor-
health-care providers’ oriented steps, which may influ-
ence the therapeutic result. Also, they need to be aware 
of the age-related changes in the pharmacokinetics of 
common dermatologic drugs, their various interac-
tions potentially occurring in the elderly, and the prin-
ciples, and evidence-based strategies for their preven-
tion, detection and management to improve adher-
ence to therapy in order to ensure the best and the 
safest treatment of dermatoses occurring in the se-
niors. By implementing these gerontopharmacologic 
principles and strategies, and a team-based, holistic, 
personalized, and multi-disciplinary professional dy-
namic approach we can achieve the desired therapeu-
tic outcome and improved quality of life for this fragile 
group of patients.
A5-P2
Voice Disorders and Voice 
Therapy in Elderly
Ana Bonetti1, Ivana Šimić2, Drago Prgomet2
1  Department of Logopedics, Faculty of Education and Rehabilitation Sciences,  
University of Zagreb
2  Department of ENT and Head and Neck Surgery, University Hospital Centre Zagreb, 
School of Medicine, University of Zagreb, Croatia
Introduction and Objectives. Voice disorders in the 
elderly are usually the result of physiological changes 
in the larynx that result in poor voice quality, vocal fa-
tigue, and vocal strain. However, part of the diagnosed 
voice disorders in this population is not due to aging. 
The aim of this paper is to present a clinical snapshot 
of such voice disorders – specifically the ones that ac-
company organic changes in the vocal cords – as well 
as to demonstrate the results of their rehabilitation. 
Methods. The study involved 23 women and 7 men 
aged 60 to 89 years with paralysis of the vocal cords 
caused by thyroidectomy (12), gastroesophageal reflux 
(LPR) (9), post-operative vagal glomus tumor (2), Re-
inke’s edema (6 ) and vocal cord polyp (1). Their self-
assessment of voice-related quality of life and their 
acoustic voice characteristics (jitter, shimmer, and har-
monic-to-noise ratio) were compared before and after 
rehabilitation. Results. After rehabilitation, the acous-
tic parameters improved significantly, indicating that, 
regardless of patient age or the impact of functional 
dysphonia in the elderly population, a good rehabilita-
tion procedure can evoke objectively measurable posi-
tive voice changes. Self-assessment revealed that poor-
er voice quality affects quality of life among these pa-
tients as well, even though they are no longer pro-
fessionally involved or maximally socially active. 
conclusion. The results of this study clearly demon-
strate the need for the involvement of elderly persons 
in voice rehabilitation and the benefits of exploring 
various rehabilitation options in daily clinical work to 
raise or preserve their quality of life.
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The Person-Centred Medical 
Interview for Elderly Patients
Marijana Braš1,2, Veljko Đorđević1
1 School of Medicine, University of Zagreb
2 University Hospital Centre Zagreb
As in other medical branches, person-centered 
medical interview is an essential and very important 
tool when caring for the elderly. The medical interview 
is an integral part of the comprehensive geriatric as-
sessment and diagnostic. The interview must include a 
complete range of biological, psychological, social and 
spiritual components. In communication with the el-
derly and the elderly patients, a special emphasis 
should be placed on certain challenges that highlight 
our communication skills, knowledge and personal 
views. It is essential to understand that older people 
will have to a much greater extent some functional dif-
ficulties that we need to be able to recognize and ac-
commodate in the interview. One of the challenges in 
communication is certainly the issue how to convey 
various bad news to patients with serious diseases. 
When communicating with this type of patients, it is 
also important to recognize some of the specific emo-
tional responses of old people to the disease. Finally, 
when we are talking about medical interview, it is of 
immense importance to organize the consultations 
with a whole family when we have an elderly patient 
with an illness. For medical practitioners, it is essential 
the knowledge how to conduct the interview which 
will have a high motivational effect on the patient and 
their health. The interview should be led in such a way 
to promote healthy aging – to point out the good parts 
and to encourage healthy life habits – while at the same 
time explaining to the patient that they can still live a 
quality life regardless the numerous illnesses. The geri-
atric assessment is interdisciplinary, requiring a high 
level of quality communication within the medical 
team. The patient and their family must be also a 
member of this team and equal participants in the 
communication process. Recognizing the importance 
of the above, we are pleased to have promoted and 
gradually introduced into the curriculum of the School 
of medicine University of Zagreb over the past ten 
years, the new modules dedicated to the communica-
tion with the elderly. In the teaching, we have included 
patients, too, through so called “model patient as a 
teacher”. This experiential learning method has proven 
to be excellent and has had the most impact on chang-
ing knowledge and attitudes among students and 
healthcare professionals.We believe that promoting 
healthy aging is a continuous process in which the im-
provement of communication is essential element.
A5-P4
Stroke and Mechanical 
Thrombectomy in Elderly
Mislav Budišić, Marina Roje Bedeković, Marijana Bosnar Puretić,  
Lidija Dežmalj Grbelja, Sara Drnasin, Lejla Ćorić
Department of Neurology, University Hospital Centre Sestre Milosrdnice,  
School of Medicine, University of Zagreb, Croatia
Introduction. The worldwide elderly population is 
rapidly growing, so absolute number of strokes is ex-
pected to significantly increase over the course of the 
next century. Therefore, the benefit of endovascular 
treatment (EVT) of stroke in the elderly becomes more 
relevant. Mechanical thrombectomy is an established 
treatment for acute ischemic stroke (AIS) due to a 
large vessel occlusion (LVO) involving the anterior ce-
rebral circulation in all patients within 6 h and in some 
selected patients with advanced imaging findings up to 
24 h from stroke onset. However, in most recent meta-
analysis (HERMES), the older patients did worse than 
the younger patients regardless of treatment modality, 
and increasing age was a strong predictor of poor out-
come. This single center analysis aimed to compare the 
outcomes of elderly patients with younger patients 
after EVT for AIS. Methods.We performed single cen-
ter retrospective analysis of 60 patients (30 of them 
over 80 years and 30 under 80 years) who received 
EVT for anterior circulation in AIS. We aimed to de-
termine 90-day good functional outcomes (modified 
Rankin Scale mRS 0–2) in patients ≥80 vs. <80 years, 
compare incidence of symptomatic intracranial hem-
orrhage (SICH), mortality and successful reperfusion 
rate (on TICI 0–2 scale) between groups. Results. 
Thirty two percent of our elderly cohort achieved good 
90-day mRS outcome compared to 40% of younger pa-
tients. Successful reperfusion rate and SICH were sim-
ilar (73% and 12% in younger group vs 76 % and 10% 
in elderly group). Morality was slightly higher in el-
derly group (22 % vs 17 %) which was most likely con-
tributed to higher prestroke comorbidity. conclusion. 
Our results support some of previous findings that al-
though older patients may have worse outcomes over-
all, there is no heterogeneity of EVT effect seen by age. 
Mechanical thrombectomy is just as effective in elderly 
patients as it is in younger ones.
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Different Faces of the Same 
Problem: Lipid-Lowering Therapy 
in the Elderly
Vlado-Vlaho Ćubela1, Iva Galić2, Ante Pašalić3, Petar Bešlić3, Edvard Galić3
1 Zagreb county Health Center, Croatia
2 School of Medicine, University of Zagreb, Croatia
3 Clinical Hospital Centre Sveti Duh, School of Medicine, University of Zagreb, Croatia
Introduction and Objectives. At least 85 million 
patients in Europe suffer from cardiovascular diseases 
which are the cause of 3,9 million deaths per year. 
Most of them are elderly people over 65 years old, who 
have an indication for lipid-lowering drug therapy. 
However, there is a question whether benefits of this 
treatment arises its harms considering frequent co-
morbidities in elderly population. Methods. Four 
types of patients that we meet daily in medical practice 
will be outlined. Their cardiovascular risk according to 
SCORE (Systematic Coronary Risk Estimation), pa-
tient assessment, blood pressure (BP), laboratory val-
ues: TC, HDL, LDL, eGFR and life expectancy, will be 
calculated. Given the calculated parameters and com-
bined with an individual approach, decision of using 
lipid therapy will be made. Results. The first patient, 
female, 65 years old, BP 140/80 mmHg, TC 5.9 
mmol/L, HDL 1.4 mmol/L, LDL 3.5 mmol/L, eGFR 89 
mL/min/1.73m², non-smoker. 10-year CV risk: 4%. 
This patient belongs to the moderate risk group 
(SCORE ≥1% and <5%) and her LDL values are 3.5 
mmol/L with no indication for initiation of therapy 
(IIa/A). The second patient, male, 65 years old, BP 
140/80 mmHg, TC 4.9 mmol/L, HDL 0.9 mmol/L, 
LDL 3.1 mmol/L, eGFR 65 mL/min/1.73m², non-
smoker. 10-year CV risk: 9%. This patient is in the 
high-risk group (SCORE ≥5% and <10%) and his LDL 
is 3.1 mmol/L, which means that therapy is recom-
mended (I/A). The third patient, female, 80 years old, 
BP 150/90 mmHg, TC 6.9 mmol/L, HDL 0.7 mmol/L, 
LDL 4.5 mmol/L, eGFR 55 mL/min/1.73m², smoker 
with documented ASCVD. This patient due to ASCVD 
belongs to the very high risk group and therapy is rec-
ommended (LDL goal <1.4mmol/L) (I/A). The fourth 
patient, male, 80 years old, BP 150/90 mmHg, TC 7.8 
mmol/L, HDL 1.1 mmol/L, LDL 5.1 mmol/L, eGFR 
<30 mL/min/1.73m², smoker with documented de-
mentia and heart failure. Due to severe CKD (eGFR 
<30 mL/min/1.73m²), this patient belongs to the very 
high risk group, LDL is 5.1 mmol/L, which requires 
the gradual introduction of therapy at lower doses 
(I/C). Life expectancy is 3.3 years. conclusions. Ac-
cording to the guidelines, particular attention should 
be paid to life expectancy and in some patients ap-
proach should be individual. In these cases, it is quite 
clear that it makes sense to introduce the therapy to 
the second and third patient, since their life expectan-
cy is long enough for the therapy to reach its maxi-
mum effect, which takes 2–3 years. However, if the last 
case is looked at, the efficacy of the therapy depends on 
life expectancy and the dose should be modificated de-
pending on renal function and other comorbidities.
A5-P6
Therapeutic Options  
of Non-melanoma Skin Cancer  
in Elderly
Romana Čeović, Mikela Petković, Zrinka Bukvić Mokos
Department of Dermatology and Venereology, University Hospital Centre Zagreb,  
School of Medicine, University of Zagreb, Croatia
Non-melanoma skin cancer (NMSC) is the most 
common human cancer, with increasing incidence in 
the last decades. Cumulative sun exposure has the 
main role in the development of NMSC, so a higher 
prevalence of NMSC in the elderly is expected. A me-
dian age at diagnosis is 71 years. Of all NMSC, approx-
imately 80% include basal cell carcinoma (BCC) and 
20% squamous cell carcinoma (SCC). Other skin tu-
mors account for about 1% of NMSC. In the elderly, 
therapy for NMSC can be surgical and nonsurgical. 
Surgical treatment of NMSC is the most effective treat-
ment that provides high cure rate of over 90% for both 
SCC and BCC, and over 95% for BCC. Despite the 
high cure rates achieved with surgery, this treatment 
modality is associated with the risk of morbidities such 
as infections, which may be fatal in this age group. 
Other therapeutic modalities depend on tumor local-
ization, histological type, and biologic behavior, as 
well as patient comorbidities, age, and life expectancy. 
Nonsurgical treatments include cryotherapy, local 
therapies (imiquimod, 5-fluorouracil, ingenol-mebu-
tate, and diclofenac), photodynamic therapy, radio-
therapy, and hedgehog inhibitors. Some of these treat-
ments can be combined with curettage and electrodes-
iccation for better outcomes. Every treatment modality 
has advantages and disadvantages that must be care-
fully considered individually. Because the facial area is 
the most common localization of NMSC, treatment 
modalities with better cosmetic outcome are preferred. 
Many times, despite good clinical condition, a surgery 
is refused by the patient because of their age. Patient 
life expectancy, functional and socioeconomic status, 
and quality of life should be taken in consideration 
when choosing the most suitable treatment modality 
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for this non-fatal disease. Surgical excision after the 
procedure requires outpatient visits, which can be in-
convenient because older patients are dependent on 
others because of the transport and a home care. On 
the other hand, nonsurgical treatments also require 
outpatient visits because of the novel applications 
which are sometimes unfamiliar to the patients. After 
choosing the best therapeutic option for a patient, it is 
crucial that the patient’s quality of life is preserved in 
this sensitive age.
A5-P7
Characteristics of Multiple 
Sclerosis in Elderly Patients
Lidija Dežmalj Grbelja
Department of Neurology, University Hospital Centre Sestre Milosrdnice,  
School of Medicine, University of Zagreb, Croatia
Introduction. Multiple sclerosis (MS) is an autoim-
mune chronic demyelinating disease of the central 
nervous system that usually starts between 20 and 40 
years. Rarely, in about less than 10% , it starts after age 
50. Currently, approximately a quarter of people with 
MS are mature adults over 65 years old. Methods. We 
have analyzed demographic characteristics of patients 
aged ≥65 years, clinical data including type of MS, age 
of disease onset, duration, Expanded Disability Status 
Scale (EDSS) and type of treatment. Results. Among 
133 patients, 12 (9.02%) were ≥65 years old, 9 (75%) 
was female and 3 (25%) male. The youngest patient 
was 66 and the oldest 86 years old. The average age was 
73.6 years. The average age of disease onset was 40.4 
years, ranging between 25 and 63 years. Th average 
disease duration was 33.2 years, range between 8 and 
48 years. The most common type of disease was sec-
ondary progressive MS, present in 8 patients (66.7%), 
2 (16.7%) patients had relapsing remitting MS and 2 
(16.7%) primary progressive MS. The average EDSS 
was 4.5, range between 1 and 9. Most patients, 91.7%, 
received only symptomatic treatment, 1 patient took 
immunomodulatory drug. conclusion. This small 
pilot study on characteristics of MS in elderly patients 
proved data found in the literature. As in the young 
age, female patients dominate. Longer disease dura-
tion means more frequent transition to secondary pro-
gressive MS and higher EDSS, while in the late onset of 
MS, after age of 50, primary progressive MS is more 
common. Immunomodulatory drugs, according to 
Croatian Health Organisation, until 2018 were re-
served for patients younger than 55 years. Most pa-
tients in our study were treated only by symptomatic 
treatment, which could explain higher EDSS and pro-
gressive type of disease.
A5-P8
Outcomes and Patient Satisfaction 
in Women Undergoing Three 
Different Operating Techniques 
for Pelvic Organ Prolapse  
– a Pilot Study
Držislav Kalafatić1, Slavko Orešković1, Lana Škrgatić3, Iva Miškulin2
1  Division of Gynecological Surgery and Urogynecology,  
Department of Obstetrics and Gynecology, University Hospital Centre Zagreb,  
School of Medicine, University of Zagreb, Croatia
2  University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Croatia
3  Division of Reproductive Endocrinology and Reproductive Medicine,  
Department of Obstetrics and Gynecology, University Hospital Centre Zagreb,  
School of Medicine, University of Zagreb, Croatia
Introduction and Objectives. There are different 
methods for surgical management of pelvic organ pro-
lapse. Surgical treatment includes vaginal native tissue 
repair, vaginal augmentation with mesh, and laparo-
scopic approach. The aim of this pilot study was to 
compare outcomes and patient satisfaction between 
three different operating techniques in a single hospi-
tal centre. Methods. A retrospective cohort study in-
cluded total of 60 women who underwent surgery for 
apical and anterior prolapse. They were divided into 
three equal groups according to operating technique: 
vaginal native tissue repair (N=20), vaginal augmenta-
tion with mesh (N=20) and laparoscopic lateral sus-
pension with mesh (N=20). Data collected included 
baseline patients characteristic (age, BMI, menopausal 
status, prior surgery), intra and perioperative variables 
(operative time, hospital stay, haemorrhage, wound 
infection, urinary complications) and six month fol-
low up outcomes (recurrent prolapse, dyspareunia, de 
novo urinary incontinence or urgency, patient satis-
faction calculated on scale 1–10). Results. Baseline 
characteristics of women included were similar. The 
mean operating time was significantly longer in the 
laparoscopic lateral suspension group (95 min) when 
compared with other two groups (p < 0.01). Neverthe-
less, hospital stay was shorter in aforementioned group 
(p<0.001). Further perioperative complications were 
rare and comparable between the groups. During the 
six-month follow-up period, no prolapse recurrence 
and mesh erosion were observed in any group. De 
novo stress urinary incontinence and urgency were in-
frequently observed and comparable between the 
groups. Overall satisfaction was higher in laparoscopic 
lateral suspension group (p<0.05). conclusion. No 
difference is found in complication rates and short-
term outcomes between three different surgical tech-
niques for apical and anterior prolapse. Nevertheless, 
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shorter hospital stay as well as higher overall satisfac-
tion confirms laparoscopic lateral suspension as a 
promising endoscopic prolapse surgery technique. Fu-
ture prospective studies with larger sample sizes dem-
onstrating the long-term outcomes are warranted to 
confirm these conclusions.
A5-P9
Osteoarthritis – Leading Cause  
of Disability in the Elderly
Boris Karanović, Ivan Padjen, Branimir Anić
Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, 
University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Croatia
Introduction and objectives. Osteoarthritis (OA) is 
a slowly progressive musculoskeletal disorder associ-
ated with increased age and is characterized by joint 
pain and tenderness, limitation of motion, joint de-
formity and instability. It has long been considered a 
noninflammatory process, but new insights suggest a 
role of proinflammatory mediators and proteases 
therefore enabling development of new treatment tar-
gets. Methods. Pathological findings in articular carti-
lage, bone, synovium and soft tissues of patients with 
OA are similar and vary in the degree of damage, sug-
gesting a uniform response to various insults. Multiple 
risk factors for developing OA have been identified, 
including age, obesity, joint injury, genetics, gender, as 
well as anatomical factors. The pathogenesis of osteo-
arthritis involves various cytokines, chemokines and 
proteases and resembles that of a chronic nonhealing 
wound. There is growing evidence implying activation 
of the innate immune system as a result of tissue dam-
age. Epigenetic changes contribute to development of 
OA as well and are being actively investigated. Results. 
Available treatment modalities consist of pain man-
agement but no treatment has been proven to alter 
the structural progression of the disease. Agents inhib-
iting catabolic processes and those stimulating ana-
bolic processes, as well as drugs that modify inflam-
matory pathways and bone remodelling are being in-
vestigated and are reffered to as disease-modifying OA 
drugs (DMOADs) or structure-modifying OA drugs 
(SMOADs). Investigational drugs targeting pain have 
focused on inhibiting nerve growth factor. conclu-
sion. Osteoarthritis is the most common form of ar-
thritis. Since it affects mainly the elderly and is associ-
ated with substantial disability and reduced quality of 
life, it represents a great burden for the aging popula-
tion. Novel insights into pathophysiology of the dis-
ease promise new treatment modalities, as opposed to 
current treatment targeting symptomatic relief.
A5-P10
Therapeutic Movement Therapy 
(TMT) and the Healthy Lifestyles 
(HLS) Education in the Day 
Hospital (DH) – Reflections  
and Suggestions
Sanja Martić-Biočina, Perla el Hasan, Zlata Pjević, Vesna Barić,  
Kristina Draguzet
University Psychiatric Hospital Vrapče, Zagreb, Croatia
Therapeutic movement therapy (TMT) and the 
healthy life styles (HLS) education in the Day Hospital 
have been successful part of the program of the Day 
Hospital for the patients who suffer from depression, 
anxiety, grief , psychosomatic and stress related disor-
ders, treated within this program. Patients who are 
treated are both sex, ages between 18–65, majority in 
the middle ages, with somatic diagnosis as comorbid-
ity. Taking care of body helps to improve wellbeing. In 
this poster we will present patients´ reflections and 
suggestions about this part of the program.
A5-P11
Assessing Fitness to Work Among 
Older Workers: Literature Review
Milan Milošević, Hana Brborović, Roko Žaja
Department for Environmental Health, Occupational and Sports Medicine,  
Andrija Štampar School of Public Health, School of Medicine, University of Zagreb, 
Croatia
Introduction and Objectives. Decreases in physical 
and mental functional ability due to aging can impair 
work capacity, productivity and fitness for work among 
older workers. There is no precise, generally recog-
nized age at which someone is considered as an older 
worker. Some studies have focused on workers older 
than 55, while other studies examined those 45 years 
or older. It is vital to make appropriate fitness to work 
assessment of older workers duo to serious increase of 
aged working population. Objective of our study is to 
summarise current situation in assessing fitness to 
work of older workers from data available in recent lit-
erature. Methods. Literature review has been made in 
PubMed database regarding following key words: age-
ing worker; fitness to work; functional capacity; work 
ability. We focused our search for time period of past 
20 years. Results. We found only five publications that 
satisfied are inclusion criteria. All studies agreed that 
tong-term health issues increase with age. At the same 
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time, mental and physical fitness are closely related 
and should be assessed together. Conclusion of fitness 
to work assessment is predisposed by the interface 
among functional capacity, health, the type of work, 
and options for work accommodation or change. In 
general, studies report that older workers exhibit lesser 
turnover, more commitment to the workplace, and 
have more positive work values. Absenteeism is less 
prevalent in relation to younger workers, although it is 
longer when it is caused by the injury or chronic ill-
ness. With respect to clinical and/or laboratory mea-
surements, some authors have recommended the use 
of a ‘work ability index’ for specific occupations as a 
practical means of selecting the appropriate worker for 
the job. Such index has been made at Finnish Institute 
of Occupational Health as an instrument used in oc-
cupational health care and research to assess work 
ability of workers during health examinations and 
workplace surveys. conclusions. Appropriate under-
standing of the work nature and workplace settings are 
essential for any fitness to work assessment among 
older workers. The assessment should include physi-
cal, mental and social capacity, as well as assessment of 
any disability. Occupational physicians have an impor-
tant role in making longer working lifetimes as possi-
ble with productive and healthy older workers.
A5-P12
Is Ischemic Heart Disease as Huge 
Problem as We Think, or Is It 
Much Bigger?
Ante Pašalić1, Petar Bešlić1, Vlado-Vlaho Ćubela2, Iva Galić3, Edvard Galić1
1 Clinical Hospital Centre Sveti Duh, School of Medicine, University of Zagreb, Croatia
2 Zagreb county Health Center, Croatia
3 School of Medicine, University of Zagreb, Croatia
Ischemic heart disease (IHD) is a major cause of 
morbidity and mortality among elderly, as the age rep-
resents the strongest risk factor for development of the 
atherosclerotic changes along the arterial tree. Beside 
age, older patients are more exposed to many other 
known cardiovascular risk factors, especially arterial 
hypertension, diabetes mellitus, dyslipidemia, renal 
dysfunction, smoking etc. Many different studies have 
demonstrated a higher prevalence of advanced coro-
nary artery disease (CAD) in elderly, like severe calci-
fications, obstructive lesions of coronary arteries, 
commonly affected left main coronary artery, multi-
vessel disease etc. From epidemiological point of view, 
according to famous trials NHANES, FHS, CHS, men 
older than 80 years of age are more affected with CAD 
than women, who present more likely with chronic 
coronary syndrome. Older patients often have atypical 
clinical presentation, and according to MESA and 
CHS trials one part of them have subclinical disease 
assessed by carotid intimal media thickness or coro-
nary artery calcium. On the other hand, GRACE trial 
showed that elderly present more frequently with 
non–ST-segment elevation myocardial infarction 
(NSTEMI), and unstable angina (UA). Only 33% of el-
derly are revascularised after ACS, while according to 
CRUSADE trial approximately 40%. Prognosis of such 
patients is unfavourable due to higher incidence of 
mortality, which reaches up to 50% at 3 years follow 
up. In EuroHeart survey in hospital mortality for ACS 
for people older than 85 years of age is approximately 
17%. ACS in elderly is more complicated with various 
conditions such as cardiogenic shock, heart failure, 
papillary muscle rupture, malignant ventricular tachy-
arrhytmias, heart blocks, etc. Eventually, older people 
are more prone to develope second type of myocardial 
infarction, most frequently due to anemia, respiratory 
failure, infections. To date, the major problem repre-
sents small number of older patients recruited in ACS 
trials. Large registries like GRACE, NRMI and CRU-
SADE involve just under 30 % of STEMI and approxi-
mately 40% of NSTEMI patients. Stated facts leave for 
the task on future trials to involve more elderly in their 
investigations, therefore patophysiology, presentation 
and treatment can be better understood.
A5-P13
Depression and Quality of Life  
in Patients with Epilepsy – Single 
Centre Experience
Željka Petelin Gadže1, Katarina Ivana Tudor1, Maja Živković2,  
Andreja Bujan Kovač1, Biljana Đapić Ivančić1, Sibila Nanković1,  
Vlatko Šulentić1, Ira Brezak3, Petra Nimac Kozina1, Barbara Sitaš1, 
Borislav Radić1, Monika Mudrovčić4, Zdravka Poljaković1, Sanja Hajnšek5
1  Department of Neurology, University Hospital Centre Zagreb, School of Medicine, 
University of Zagreb, Croatia
2  Department of Psychiatry and Psychological Medicine, University Hospital Centre 
Zagreb, School of Medicine, University of Zagreb, Croatia
3  Croatian Association for Behavioral–Cognitive Therapies, Zagreb, Croatia
4  University Hospital for Infectious Diseases “Dr. Fran Mihaljević”, School of Medicine, 
University of Zagreb, Croatia
5 School of Medicine, University of Zagreb, Croatia
Introduction and objectives. Epilepsy is often asso-
ciated with comorbid psychiatric illnesses and the 
most frequent of these, in around 40% of patients, is 
major depressive disorder. Compared to general popu-
lation epidemiological studies show a consistent in-
creased prevalence of depression in epilepsy. The main 
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aim of this study was to evaluate the relationship be-
tween epilepsy, antiepileptic drugs (AEDs) and de-
pression. We also wanted to evaluate possible associa-
tion between depressive symptoms in patients with 
epilepsy with the quality of life (QoL). Methods. This 
was a prospective cross-sectional study carried out at 
the tertiary teaching hospital (University Hospital 
Centre Zagreb, Croatia) with Ethics committee ap-
proval. Questionnaires evaluating depressive symp-
toms and QoL were administered to consecutive pa-
tients treated in the Referral Centre of the Ministry of 
Health of the Republic of Croatia for Epilepsy. Depres-
sive symptoms were evaluated using Hamilton Rating 
Scale for Depression (HAM- D17). Quality of life was 
assessed using Quality of life in epilepsy-31 inventory 
(QOLIE-31). Statistical analysis was done using statis-
tical software IBM Corp. Released 2011. IBM SPSS 
Statistics for Windows, Version 20.0. Armonk, NY: 
IBM Corp, using t-test, one way ANOVA, post hoc 
Scheffe test, Bonferroni, Tukey test, and Pearson cor-
relation coefficient. Results. 108 patients (63% women, 
37% men; mean age 39.54 ± 15.91 years) with epilepsy 
were included. 14.8% of patients had focal, 35.2% gen-
eralised and 40.7% both types of epilepsy. Majority of 
patients (65.74%) were on two and more AEDs and 
quarter was on monotherapy (25%); 42% were on 
newer, 19% on older and 39% on both AEDs. Mean 
total score on HAM- D17 was 9.94 ± 8.18 (men – mean 
total score 10.16 ± 8.85, women – mean total score 
9.81 ±7.84). There were no significant differences on 
HAM- D17 regarding gender and age. We didn’t find 
statistically significant differences regarding AEDs 
(older vs. newer AEDs, or both types AEDs) and re-
sults on HAM- D17, nor between the type of epilepsy 
and results on HAM – D17. We found strong negative 
correlation between the higher QoL and HAM – D17 
(p=0.000). conclusions. Results of this study evaluat-
ing depressive symptoms in patients with epilepsy 
demonstrate that our patients mainly experience mild 
depressive symptoms, with no significant differences 
on HAM- D17 regarding gender and age. Patients with 
epilepsy with less pronounced depressive symptoms 
were found to have higher QoL. We did not find statis-
tically significant differences regarding the type of epi-
lepsy and results on HAM – D17, nor between the 
AEDs (older vs. newer AEDs, or both types AEDs) 
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Aging is a complex phenomenon leading to numer-
ous changes in the physiological systems of the body. 
Age-related diseases are closely related to age-induced 
immune dysfunction, by which reductions in the effi-
ciency and specificity of the immune system are termed 
„immunosenescence“. Immunosenescence predispose 
aged individuals to development of cerebrovascular 
risk factors.In neuro intensive care units several neu-
ro-related diseases including stroke are related to im-
munosenescence and neuroinflammation in the elder-
ly. Profound systemic immunodepression occurs as 
early as 12 hours after ischemic stroke and may persist 
for several weeks. T lymphocytes are central to the de-
velopment of a sustained inflammatory response. 
There is evidence that they accumulate in the post-
ischemic brain within a few hours of reperfusion. In-
fectious complications, predominantly chest and uri-
nary tract infections, occur in many stroke patients 
within the first days of the stroke. The development of 
an infection soon after the stroke is associated with 
worse outcome. The immune system is also a key play-
er in central nervous system repair and maintenance 
that undergoes a profound remodeling process over 
the lifetime and has a major impact on individual’s 
poststroke neurorehabilitaion, survival and outcome. 
Several advanced countries with superaged societies 
face the new challenge of improving the long-term 
prognosis of stroke patients. A better understanding of 
the multiple biological phenomena leading to diseases 
via the immunosenescence associated with inflam-
maging provides a powerful target for interventions to 
increase the healthspan of elderly subjects.
A5-P15
Preparing Life for Healthy Longevity
Mirna Sisek-Šprem1, Ninoslav Mimica1,2, Mira Štengl-Martinjak1,  
Aida Križaj1, Ana Papić1
1 Department of Biological Psychiatry and Psychogeriatrics,  
University Psychiatric Hospital Vrapče, Zagreb, Croatia
2 University of Zagreb School of Medicine, Zagreb, Croatia
Psychiatry, more than any other field of medicine, 
needs to view a person as a whole, recognizing and ac-
cepting every patient’s individuality. A personalized 
approach is very important when working with pa-
tients of older age for multiple reasons: these patients 
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come to us with a lifetime of trauma, they not only 
have medical but also social issues, they are isolated 
and less functional, aside from psychological disor-
ders, they also have somatic comorbidities and are 
generally more sensitive to pharmacotherapy. They are 
a particularly vulnerable group of patients in every 
way. This is why with these patients psychopharma-
ceuticals are prescribed very cautiously and various 
support therapy techniques are used, which includes 
stimulating patients towards a meaningful life. The im-
portance of seeking meaning in life and positive atti-
tudes towards life has been talked about since ancient 
times; Aristotle speaks of eudaimonia and resilience is 
a popular term today. For the past ten years research 
has been conducted on the impact that finding mean-
ing in life has on a person’s overall health and in reduc-
ing the risk of certain diseases, including dementia, 
stroke and heart attack, by increasing cognitive reserve 
and reducing the infection response. Frankl, the 
founder of logotherapy, states that a person’s basic 
need is to search for purpose and that he/she is willing 
to suffer if that suffering has a purpose, that purpose in 
life (and in the moment) is individual and must be 
sought out daily on an individual level. Logotherapy, 
as a method of psychotherapy, encourages patients to 
look for strengths within them and then direct them-
selves towards meaningful action, which is the most 
satisfying when directed at others. An individual ap-
proach is emphasized; together with the patient, his/
her strengths, talents and aspirations from youth are 
sought out and encouraged, focusing on identifying 
positive moments. By designing daily activities, espe-
cially those that restore the patient’s sense of being 
needed by others, that they should not give up because 
of those around them (family members), a brighter 
perspective is created, symptoms of anxiety and de-
pression are eliminated and dementia is slowed 
through cognitive skills training. This approach 
achieves the preventative and curative effect that is 
necessary in order to increase the quality of life of the 
elderly and to increase lifespan.
A5-P16
Current Approaches  
to the Prevention and Treatment 
of Age-Related Macular 
Degeneration
Domagoj Vlašić, Helena Kaštelan, Antonela Gverović Antunica
Department of Ophthalmology, Dubrovnik General Hospital, Croatia
Macular degeneration, also known as age-related 
macular degeneration (AMD or ARMD), is a degen-
erative ailment affecting the macula. It is defined by 
the presence of distinct clinical findings, including 
drusen and retinal pigment epithelium (RPE) changes, 
in the absence of another malady. Later stages of the 
disease are correlated with impairment of vision. AMD 
is multifactorial in aetiology where age and heredity 
have a central place in the disease occurrence. The re-
cent epidemiological studies have shown that there are 
about 0.4% of people between 50 and 60 , 0.7% of peo-
ple between 60 to 70, 2.3% of those 70 to 80, and near-
ly 12% of people over 80 years old diagnosed with 
AMD. Furthermore, smoking and obesity are associ-
ated with a higher prevalence of the disease. Modern 
classification divides AMD into two main types: non-
exudative (dry, non-neovascular) holding around 90% 
of diagnosed disease and exudative (wet, neovascular) 
associated with more prompt progression of sight loss. 
The disease is diagnosed by funduscopic examination 
where the presence of multiple drusen is frequent for 
early AMD. The drusen may appear confluent in inter-
mediate AMD with significant pigment variations and 
pigment accumulation. Furthermore, the retinal pig-
ment epithelium (RPE) often appears atrophic, with 
easier visualization of the underlying choroid vascular 
plexus. On the other hand, advanced exudative AMD 
appears with choroidal neovascularization, RPE eleva-
tion or haemorrhage. Further procedures such as fluo-
rescein angiography, Amsler grid evaluation, ocular 
coherence tomography (OCT) of the retina and ocular 
coherence tomography angiography (OCTA) of the 
retina confirm the diagnosis of AMD. Disease man-
agement can be divided into prophylaxis and active 
treatment. The first focus on the prevention of the 
non-exudative AMD, whereas the active approach is 
more common for the exudative AMD. Preventive ef-
forts include exercising, eating well, and not smoking. 
No remedy or treatment returns already lost vision. In 
the exudative form, anti-VEGF medication injected 
into the eye or less ordinarily laser coagulation or pho-
todynamic therapy may decrease the disease progres-
sion. Antioxidants and minerals do not appear to be 
useful for prevention. However, dietary supplements 
may slow the progression of the disease itself. The 
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most recent disease control approach include subreti-
nal stem cell transplantation and intravitreal injection 
of ciliary neurotrophic factor, steroid inserts and neu-
roprotective drugs, including brimonidine.
A5-P17
Why Care About Nutrition  
and Eating Habits in Early Life? 
Impact on Healthy Ageing
Orjena Žaja
Department of Pediatrics, University Hospital Centre Sestre Milosrdnice,  
School of Dental Medicine, University of Zagreb, Croatia
Introduction and objectives. The rapid increase of 
non-communicable diseases (NCDs) is a major global 
health concern. The increase has happened too fast 
thus suggests that epigenetic phenomena may play a 
pivotal role. The most critical period in life is during 
the first 1000 days (from conception until 2 years) that 
offers a critical window of opportunity to shape both 
short and long-term health, while nutrition plays a 
crucial role. An imbalanced intake of nutrients can 
have profound effects on the child development, in-
cluding risk of NCDs in later life. Meeting the specific 
nutritional needs in this period can positively influ-
ence health outcome throughout life and therefore 
represents the first step towards healthy aging. Feeding 
difficulties (FDs) are among the most common pediat-
ric problems. Incidence is higher in children with psy-
chomotor developmental disorders and chronic ill-
nesses. According to some authors, 25–30% of parents 
report specific feeding problems, and 1–2% have seri-
ous problems classified as early feeding disorders 
(EFDs). This difficulty significantly increase the risk of 
malnutrition and can adversely affect healthy aging. 
The aim of this research was to analyze the character-
istics of children with FDs in our department and ap-
plied therapeutic interventions. Methods. Medical 
chart retrospective analysis of children who attended 
department due to FDs in the past two-year. Results. 
During the analyzed period, a total of 174 children 
with nutrition-related disorders were treated (FDs and 
eating disorders). Fifty-seven, average age 16.31±9.2 
months, had FDs. Only 6/47 had a severe form (EFDs), 
while rest had mild form of FDs. Most prevalent was 
selective form of FDs, and infantile anorexia the rarest. 
On average, the difficulties lasted for 7.29±5.32 month 
before treatment. Organic diseases were excluded 
(GERD, food allergy, celiac disease). 40/57 children 
presented with failure to thrive and 35/57 had signs of 
malnutrition. Regarding risk factors, 24/57 children 
had psychomotor development difficulties and 13/57 
had perinatal complications. Therapeutic interven-
tions implied parental reassurance, education on feed-
ing patterns and nutritional supplementations. Only 
children with EFDs were included in further multidis-
ciplinary treatment. conclusions. Feeding difficulties 
are common in pediatric practice, but are not seen as a 
potentially serious problem that can have long-term 
health effects. When recognized early, the intervention 
is simple and significantly reduces the risk of malnu-
trition and the negative impact on healthy aging. Thus, 
timely recognition and intervention are an important 
goal, for families and health professionals.
A5-P18
Clinical Practices  
for Improvement of Psoriasis  
in Elderly
Kristina Žužul1, Zrinka Bukvić Mokos2, Romana Čeović2
1 School of Medicine, University of Zagreb, Croatia
2  Department of Dermatology and Venereology, University Hospital Centre Zagreb, 
School of Medicine University of Zagreb, Croatia
Psoriasis is a systemic inflammatory disease of mul-
tifactorial etiology, in which an increased release of 
proinflammatory cytokines and activation of the im-
mune system cause damage to various tissues and or-
gans. It is a chronic disease affecting 2–3% of the pop-
ulation, characterized by inflammation and scaling of 
the skin, but not limited to it. Mild psoriasis is gener-
ally treated with topical therapy, while phototherapy, 
oral systemic medications or biologic therapy are 
treatment options for moderate to severe disease. Tak-
ing into account the chronic course of this disease and 
the continuing rise in life expectancy, the prevalence 
of psoriasis among the elderly will further increase, 
which makes management of psoriasis in the elderly 
an important health care problem.
Management of psoriasis in elderly patients may be 
challenging since they are often excluded from clinical 
trials, and the data regarding efficacy and safety in this 
population is lacking. Consequently, some dermatolo-
gists recommend only topical therapy and avoid pre-
scribing systemic therapy, which may lead to inade-
quate treatment response in this population. Individu-
alized treatment to each elderly patient should be pro-
vided due to possible drug-induced or aggravated 
psoriasis, higher prevalence of comorbidities, poly-
pharmacy, adverse effects, self-care capability and 
quality of life. 
Topical therapy is probably the safest option for 
treating elderly patients with psoriasis, although topi-
cal corticosteroids should be used with caution due to 
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the physiologic changes in older skin and a higher risk 
of cutaneous side effects. The physical limitations and 
dependence on caregivers should also be taken into 
account, as compliance may be reduced due to diffi-
culty in applying topical agents. Due to a higher preva-
lence of hypertension and decreased renal and hepatic 
function in the elderly, special caution should be taken 
when prescribing conventional systemic therapy – 
methotrexate, cyclosporine, and acitretin. Biologic 
therapy is more often initiated in younger than in el-
derly patients, although it may be a safer option than 
conventional systemic therapy in the elderly due to its 
high efficacy, a lower rate of adverse events, and lower 
frequency of hospital visits. Still, regular follow-up is 
necessary because of the increased risk of infections 
and malignancies.
Since psoriasis is becoming increasingly widespread 
in the elderly, it is surprising that studies regarding 
treatment efficacy and safety in the geriatric popula-
tion are scarce. Further clinical research on treatment 
modalities in the elderly are needed, in order to im-
prove management outcomes in this population.
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Introduction and objectives. The aging population 
rises the need for adequate education of specialist fo-
cused on medical care for elderly. Physicians should be 
trained to adopt the expertise in certain areas to chang-
ing biological functioning and communicational and 
social challenges of elderly patient. Objective of this 
study is to present the most recent educational pro-
gram for physicians providing health care for elderly 
in Croatia. Methods. Medical Faculty in Zagreb intro-
duced the postgraduate program tailored to adopt the 
most recent recommendation of UEMS to the current 
best practices in all areas of medical care for elderly 
in Croatia. The program is structured for graduated 
medical doctors. Results. Training for health care of 
elderly is presents in almost of all specialty training 
programs and postgraduate education in Croatia, 
most notably in specialty training program in geriatric 
medicine. The five-year specialty training program in 
geriatric medicine includes internal common trunk 
during 22 months and specific part of specialty train-
ing program in geriatric medicine during 33 months. 
During the internal common trunk residents in geriat-
ric medicine have the same program as all other resi-
dents included in specialty training programs with in-
ternal common trunk. During specific part of specialty 
training program in geriatric medicine residents spend 
three months at internal medicine departments and 
acquire the competencies necessary for the providing 
health care for elderly, two months in training for in-
terventional diagnostic and therapeutic procedures for 
elderly, five months are reserved for neurogeriatric 
topics, five and half months for psychogeriatric topics, 
two and half months for palliative care, two months 
for rehabilitation, one and half months for orthopedics 
ant traumatology, one and half months for endocrinol-
ogy, one and half months for oncology and radiother-
apy, one month for infectology and fifteen days for 
nutrition in elderly . Specialty training program in ge-
riatric medicine includes five months for education in 
gerontology and public health. During specialty train-
ing in geriatric medicine residents spend two months 
in family medicine because family physicians are basic 
physicians in primary health care in Croatia. Specialty 
training program in geriatric medicine in Croatia in-
cludes three months’ theoretical postgraduate educa-
tion in geriatric medicine as obligatory part of educa-
tion of this kind of medical expert. conclusion. Edu-
cation in Croatia enable physicians for providing 
health care for elderly, mostly during specialty training 
in geriatric medicine.
